[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 309
1. Dobson JM, Scase TJ: Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. J Small Anim Pract; 2007 Aug;48(8):424-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the diagnosis and management of cutaneous mast cell tumours in dogs.
  • Mast cell tumours are one of the most common tumours of the canine skin and have a reputation for being difficult to manage because of their variable clinical presentation, behaviour and response to treatment.
  • This review of recent literature on canine mast cell tumours suggests that the majority of such tumours may not be as bad as their reputation suggests.
  • Most grade I and grade II tumours can be managed successfully by good surgery.
  • Recent literature also calls into question the utility of clinical staging systems and the value of assessing surgical margins for prognosis and highlights the paucity of well-conducted, case-controlled clinical trials in assessing the efficacy of medical management of high-risk tumours.
  • In terms of more basic research, recent studies have implicated the stem cell factor receptor KIT as having a role in the aetiology of canine mast cell tumours and there appears to be an association between c-kit mutation and higher grade of tumour.
  • [MeSH-major] Dog Diseases / diagnosis. Dog Diseases / therapy. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559522.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 69
  •  go-up   go-down


2. Kisseberth WC, Murahari S, London CA, Kulp SK, Chen CS: Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines. Am J Vet Res; 2008 Jul;69(7):938-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.
  • OBJECTIVE: To determine whether exposure of canine cancer cells to histone deacetylase (HDAC) inhibitors S(+)-N-hydroxy-4-(3-methyl-2-phenyl-butyrylamino)benzamide (OSU-HDAC42) or suberoylanilide hydroxamic acid (SAHA) results in increased histone acetylation and decreased cell viability and whether any changes in viability involve induction of apoptosis or alterations in progression of the cell cycle.
  • SAMPLE POPULATION: 9 canine cancer cell lines.
  • PROCEDURES: Cells from 9 canine cancer cell lines were treated with dimethyl sulfoxide vehicle, OSU-HDAC42, or SAHA, then assays of cell viability were performed.
  • Cell cycle analysis was performed by use of propidium iodide staining and flow cytometry.
  • RESULTS-Concentrations of OSU-HDAC42 and SAHA required to achieve 50% inhibition of cell viability (IC(50)) were reached in cells of 6 and 4 canine cancer cell lines, respectively, and ranged from approximately 0.4 to 1.3 microM for OSU-HDAC42 and 0.6 to 4.8 microM for SAHA.
  • Cells from T-cell lymphoma, mast cell tumor, osteosarcoma, and histiocytic sarcoma lines were most sensitive to HDAC inhibition, with IC(50)s of < 1 microM for OSU-HDAC42 and < 5 microM for SAHA.
  • Induction of apoptosis was indicated via cleavage of caspase 3 and increases in cytoplasmic nucleosomes and the subG(1) cell population.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Micromolar concentrations of HDAC inhibitors OSU-HDAC42 and SAHA induced histone acetylation, cytotoxicity, and apoptosis in canine cancer cells.
  • [MeSH-minor] Acetylation / drug effects. Animals. Apoptosis / drug effects. Apoptosis / physiology. Blotting, Western / veterinary. Cell Cycle / drug effects. Cell Cycle / physiology. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / physiology. DNA Fragmentation / drug effects. Dogs. Dose-Response Relationship, Drug. Flow Cytometry / veterinary. Inhibitory Concentration 50

  • Hazardous Substances Data Bank. Vorinostat .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18593248.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / OSU-HDAC42 compound; 0 / Phenylbutyrates; 58IFB293JI / vorinostat
  •  go-up   go-down


3. Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O: Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med; 2008 Nov-Dec;22(6):1301-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Masitinib is safe and effective for the treatment of canine mast cell tumors.
  • BACKGROUND: Activation of the KIT receptor tyrosine kinase is associated with the development of canine mast cell tumors (MCT).
  • Time-to-tumor progression (TTP), overall survival, objective response at 6 months, and toxicity were assessed.
  • This effect was more pronounced when masitinib was used as first-line therapy, with an increase in the median TTP from 75 to 253 days (P = .001) and regardless of whether the tumors expressed mutant (83 versus not reached [P = .009]) or wild-type KIT (66 versus 253 [P = .008]).
  • CONCLUSIONS AND CLINICAL IMPORTANCE: Masitinib is safe and effective at delaying tumor progression in dogs presenting with recurrent or nonresectable grade II or III nonmetastatic MCT.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Vet Intern Med. 2010 Jan-Feb;24(1):6; author reply 7 [20391634.001]
  • [ErratumIn] J Vet Intern Med. 2009 Jan-Feb;23(1):224. Oglivie, G [corrected to Ogilvie, G]
  • (PMID = 18823406.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Thiazoles; M59NC4E26P / masitinib
  •  go-up   go-down


Advertisement
4. Isotani M, Tamura K, Yagihara H, Hikosaka M, Ono K, Washizu T, Bonkobara M: Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Vet Immunol Immunopathol; 2006 Nov 15;114(1-2):168-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
  • The gain-of-function mutations within c-kit, a protooncogene encoding KIT, induce constitutive ligand-independent kinase activation and are important for the pathogenesis of mast cell proliferative disease in humans as well as in dogs.
  • Despite the clinical importance of feline mast cell tumors, no mutation has been shown within the c-kit gene in cats.
  • In the present report, we analyzed the c-kit nucleotide sequence in the case of a cat that showed systemic mastocytosis and mastocytemia.
  • Within the c-kit cDNA prepared from the malignant mast cells, we identified an 12-bp internal tandem duplication at the region corresponding to exon 8, resulting in a four amino acid insertion between residues Thr418 and His419 within the fifth immunoglobulin-like domain of KIT.
  • The tumor masses greatly responded and were undetectable after 5 weeks of treatment.
  • Correspondingly, the number of mast cells in the peripheral blood was markedly reduced.
  • It is, therefore, considered that the internal tandem duplication within the domain contributes to the neoplastic transformation of mast cells in the cat by increasing KIT phosphorylation.
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Benzamides. Cats. Exons. Germ-Line Mutation. Imatinib Mesylate. Male. Molecular Sequence Data. Protein-Tyrosine Kinases / antagonists & inhibitors. RNA, Neoplasm / chemistry. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / veterinary. Tandem Repeat Sequences

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908071.001).
  • [ISSN] 0165-2427
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / RNA, Neoplasm; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


5. van der Luer RJ, Teske E, Rutteman GR, van den Ingh TS: [Prognosis, mitotic index and cell proliferation markers of mastocytoma in a dog]. Tijdschr Diergeneeskd; 2008 Jun 15;133(12):522-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis, mitotic index and cell proliferation markers of mastocytoma in a dog].
  • [Transliterated title] Prognose, mitose-index en proliferatiemarkers in mastocytomen van de hond.
  • [MeSH-major] Cell Proliferation. Dog Diseases / pathology. Mastocytoma / pathology. Mitotic Index. Neoplasm Staging / veterinary
  • [MeSH-minor] Animals. Biomarkers, Tumor. Dogs. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18615903.001).
  • [ISSN] 0040-7453
  • [Journal-full-title] Tijdschrift voor diergeneeskunde
  • [ISO-abbreviation] Tijdschr Diergeneeskd
  • [Language] dut
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 8
  •  go-up   go-down


6. Liu Z, Garrard WT: Long-range interactions between three transcriptional enhancers, active Vkappa gene promoters, and a 3' boundary sequence spanning 46 kilobases. Mol Cell Biol; 2005 Apr;25(8):3220-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using chromosome conformation capture technology, we demonstrate that rearranged and actively transcribed Igkappa alleles in MPC-11 plasmacytoma cells exhibit mutual interactions over 22 kb between these three enhancers and Vkappa gene promoters.
  • Very similar interactions between the enhancers are also exhibited by normal B cells isolated from mouse splenic tissue but not by germ line transcriptionally inactive alleles of T cells or P815 mastocytoma cells, which exhibit a seemingly linear chromatin organization.
  • However, S107 plasmacytoma cells that lack NF-kappaB still exhibit mutual interactions between the Igkappa gene enhancers.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12421-5 [8618913.001]
  • [Cites] Mol Cell Biol. 1996 Jun;16(6):3138-55 [8649425.001]
  • [Cites] Mol Biol Cell. 1996 May;7(5):825-42 [8744953.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):1911-22 [10688639.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(1):196-208 [11113195.001]
  • [Cites] Biochem J. 2001 Mar 1;354(Pt 2):431-8 [11171123.001]
  • [Cites] Blood. 2001 Feb 1;97(3):815-7 [11157504.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):848-54 [11526401.001]
  • [Cites] Science. 2002 Feb 15;295(5558):1306-11 [11847345.001]
  • [Cites] Annu Rev Immunol. 2002;20:301-22 [11861605.001]
  • [Cites] Curr Biol. 2002 Mar 5;12(5):R185-92 [11882311.001]
  • [Cites] Curr Biol. 2002 Mar 19;12(6):439-45 [11909528.001]
  • [Cites] Science. 2002 Apr 5;296(5565):158-62 [11935030.001]
  • [Cites] Annu Rev Biochem. 2002;71:101-32 [12045092.001]
  • [Cites] Curr Opin Cell Biol. 2002 Jun;14(3):372-6 [12067661.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32640-9 [12080064.001]
  • [Cites] Cell. 2002 Sep 6;110(5):575-85 [12230975.001]
  • [Cites] Immunity. 1997 Feb;6(2):131-43 [9047235.001]
  • [Cites] Immunity. 1997 Feb;6(2):145-54 [9047236.001]
  • [Cites] J Cell Biol. 1997 Jun 30;137(7):1459-68 [9199163.001]
  • [Cites] Curr Biol. 1997 Dec 1;7(12):930-9 [9382846.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3482-96 [9407039.001]
  • [Cites] Cell. 1997 Dec 12;91(6):845-54 [9413993.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2957-64 [9566915.001]
  • [Cites] Mol Immunol. 1998 Jul;35(10):609-20 [9823759.001]
  • [Cites] J Biol Chem. 1999 Feb 5;274(6):3285-93 [9920868.001]
  • [Cites] Mol Cell. 1999 Feb;3(2):207-17 [10078203.001]
  • [Cites] Science. 1999 Jun 11;284(5421):1790-5 [10364545.001]
  • [Cites] Mol Cell. 1999 Jul;4(1):63-73 [10445028.001]
  • [Cites] Chromosome Res. 2003;11(5):447-59 [12971721.001]
  • [Cites] Chromosome Res. 2003;11(5):513-25 [12971726.001]
  • [Cites] Chromosome Res. 2003;11(5):537-47 [12971728.001]
  • [Cites] Nat Genet. 2003 Oct;35(2):190-4 [14517543.001]
  • [Cites] Mol Cell. 2004 Jan 30;13(2):291-8 [14759373.001]
  • [Cites] Curr Opin Genet Dev. 2004 Apr;14(2):203-9 [15196468.001]
  • [Cites] Genes Dev. 2004 Jun 15;18(12):1495-509 [15198986.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(14):6393-402 [15226439.001]
  • [Cites] Nat Genet. 2004 Aug;36(8):889-93 [15273689.001]
  • [Cites] Nat Immunol. 2004 Oct;5(10):1017-27 [15378057.001]
  • [Cites] Immunogenetics. 2004 Oct;56(7):490-505 [15378297.001]
  • [Cites] Cell. 1978 Dec;15(4):1495-509 [103631.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Apr;77(4):1937-41 [6769117.001]
  • [Cites] Nature. 1980 Aug 21;286(5775):776-9 [6772972.001]
  • [Cites] Nature. 1980 Aug 21;286(5775):779-83 [6772973.001]
  • [Cites] J Exp Med. 1981 May 1;153(5):1366-70 [6788890.001]
  • [Cites] Cell. 1981 Oct;26(1 Pt 1):57-66 [6799208.001]
  • [Cites] Cell. 1983 Jul;33(3):741-8 [6409419.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 May;81(9):2650-4 [6425835.001]
  • [Cites] J Biol Chem. 1984 Jul 10;259(13):8534-44 [6429143.001]
  • [Cites] Cell. 1985 Feb;40(2):271-81 [2578321.001]
  • [Cites] Cell. 1986 Jan 31;44(2):273-82 [3002631.001]
  • [Cites] J Biol Chem. 1986 Mar 15;261(8):3838-45 [3081510.001]
  • [Cites] Cell. 1987 Jan 16;48(1):121-8 [3098435.001]
  • [Cites] Science. 1987 Jun 19;236(4808):1573-7 [3109035.001]
  • [Cites] EMBO J. 1989 Jul;8(7):1959-64 [2507312.001]
  • [Cites] Mol Cell Biol. 1991 Feb;11(2):1040-7 [1899281.001]
  • [Cites] J Biol Chem. 1992 Nov 25;267(33):23888-93 [1429727.001]
  • [Cites] Nucleic Acids Res. 2002 Oct 1;30(19):4176-85 [12364596.001]
  • [Cites] Cell. 2002 Oct 18;111(2):151-4 [12408858.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):623-6 [12426570.001]
  • [Cites] Mol Cell. 2002 Dec;10(6):1453-65 [12504019.001]
  • [Cites] J Biol Chem. 2003 Jan 24;278(4):2370-6 [12435739.001]
  • [Cites] Cell. 2003 Feb 21;112(4):403-6 [12600306.001]
  • [Cites] Trends Genet. 2003 Jun;19(6):298-302 [12801719.001]
  • [Cites] Trends Biochem Sci. 2003 Jun;28(6):277-80 [12826398.001]
  • [Cites] Chromosome Res. 2003;11(5):387-401 [12971716.001]
  • [Cites] Genes Dev. 1996 Oct 1;10(19):2478-90 [8843199.001]
  • (PMID = 15798207.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM029935; United States / NIGMS NIH HHS / GM / R01 GM059809; United States / NIGMS NIH HHS / GM / GM29935; United States / NIGMS NIH HHS / GM / GM59809
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin; 0 / DNA-Binding Proteins; 0 / Immunoglobulin Variable Region; 0 / Immunoglobulin kappa-Chains; 0 / NF-kappa B; 0 / TCF Transcription Factors; 0 / Tcf7l1 protein, mouse; 0 / Transcription Factor 7-Like 1 Protein; 0 / Transcription Factor RelA; 0 / Transcription Factors; 9004-22-2 / Globins; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC1069589
  •  go-up   go-down


7. Marconato L, Bettini G, Giacoboni C, Romanelli G, Cesari A, Zatelli A, Zini E: Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement. J Vet Intern Med; 2008 Jul-Aug;22(4):1001-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement.
  • BACKGROUND: Mast cell tumors (MCTs) with bone marrow (BM) involvement are poorly documented in dogs and are associated with a poor prognosis.
  • Imatinib was administered if tumor-associated tyrosine kinase KIT was aberrant.
  • BM infiltration with mast cells (MCs) was observed in all dogs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564225.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P: Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol; 2007 Oct;35(10):1510-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
  • Aggressive mast cell (MC) tumors are hematopoietic neoplasms characterized by uncontrolled growth of MC and resistance to conventional drugs.
  • In most cases, the tyrosine kinase (TK) receptor KIT is involved in malignant cell growth.
  • We examined the effects of four TK inhibitors (imatinib, midostaurin, nilotinib, and dasatinib) on C2 canine mastocytoma cells, as well as primary neoplastic canine MC.
  • As assessed by (3)H-thymidine incorporation experiments, all TK inhibitors produced dose-dependent inhibition of proliferation in C2 cells with the following IC(50) values: imatinib: 269 +/- 180 nM, midostaurin: 157 +/- 35 nM, nilotinib: 55 +/- 24 nM, dasatinib: 12 +/- 3 nM.
  • Growth-inhibitory effects of TK inhibitors were also observed in primary neoplastic mast cells, although IC(50) values for each drug varied from patient to patient, with midostaurin being the most potent agent in all samples tested.
  • In consecutive experiments, we were able to show that TK inhibitors cooperate with each other in producing growth inhibition in C2 cells with synergistic effects observed with most drug combinations.
  • In flow cytometry and TUNEL assay experiments, growth-inhibitory effects of TK inhibitors were found to be associated with cell-cycle arrest and apoptosis.
  • Together, these data show that several TK-targeting drugs induce apoptosis and inhibit proliferation in canine mastocytoma cells in vitro, and that synergistic drug interactions can be obtained.
  • Clinical trials are now warranted to explore whether these TK inhibitors also counteract growth of neoplastic cells in vivo in patients with aggressive MC tumors.
  • [MeSH-major] Dog Diseases / drug therapy. Hematologic Neoplasms / drug therapy. Hematologic Neoplasms / veterinary. Mast-Cell Sarcoma / drug therapy. Mast-Cell Sarcoma / veterinary. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Dogs. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm / drug effects. Drug Screening Assays, Antitumor. Drug Synergism. Humans. Mast Cells / metabolism. Mast Cells / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681669.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


9. Seidel A, Gueck T, Fuhrmann H: The Influence of long-chain polyunsaturated fatty acids on total lipid fatty acid composition of a canine mastocytoma cell line. J Vet Med A Physiol Pathol Clin Med; 2005 Jun;52(5):219-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Influence of long-chain polyunsaturated fatty acids on total lipid fatty acid composition of a canine mastocytoma cell line.
  • Cutaneous mast cells are considered as key immune effectors in the pathogenesis of canine atopic dermatitis (CAD).
  • These cells release immediate-phase and late-phase mediators of inflammation.
  • The purpose of this study was to examine the effects of n6- and n3-fatty acids on the fatty acid composition of canine mastocytoma cells (C2) as a possible model for CAD.
  • Cell growth was examined for 11 days in all media.
  • Cell growth increased from days 1 to 8 and decreased thereafter in all media conditions.
  • The fatty acids supplied did not influence cell growth.
  • The cells were harvested after 8 days for fatty acid analysis.
  • [MeSH-major] Dermatitis, Atopic / veterinary. Disease Models, Animal. Dog Diseases / pathology. Fatty Acids, Unsaturated / pharmacology. Inflammation Mediators / metabolism. Mast Cells / drug effects
  • [MeSH-minor] Animals. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Docosahexaenoic Acids / administration & dosage. Docosahexaenoic Acids / pharmacology. Dogs. Mastocytoma / pathology. Mastocytoma / veterinary. gamma-Linolenic Acid / administration & dosage. gamma-Linolenic Acid / pharmacology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943605.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids, Unsaturated; 0 / Inflammation Mediators; 25167-62-8 / Docosahexaenoic Acids; 78YC2MAX4O / gamma-Linolenic Acid
  •  go-up   go-down


10. Taney K, Smith MM: Resection of mast cell tumor of the lip in a dog. J Vet Dent; 2009;26(1):28-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of mast cell tumor of the lip in a dog.
  • A 10-year-old Boston terrier dog was presented for treatment of a 2-cm mast cell tumor of the left upper lip and nasal planum immediately adjacent to the philtrum and ventral to the nares.
  • [MeSH-major] Dog Diseases / surgery. Lip Neoplasms / veterinary. Mast-Cell Sarcoma / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Vet Dent. 2009 Summer;26(2):120
  • (PMID = 19476085.001).
  • [ISSN] 0898-7564
  • [Journal-full-title] Journal of veterinary dentistry
  • [ISO-abbreviation] J Vet Dent
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Bulat V, Mihić LL, Situm M, Buljan M, Blajić I, Pusić J: Most common clinical presentations of cutaneous mastocytosis. Acta Clin Croat; 2009 Mar;48(1):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The term mastocytosis is referred to as an array of uncommon, usually sporadic, heterogeneous clinical illnesses that result from the hyperplasia of tissue mast cells.
  • The characteristic presentation of mastocytosis consists of cutaneous manifestations: either a solitary mastocytoma, urticaria pigmentosa, or less commonly, diffuse cutaneous mastocytosis.
  • Mastocytosis may also be manifested as mastocytoma, a rare, benign, pediatric tumor that results from hyperplasia of mast cells in papillary dermis in the first few weeks of life.
  • The prognosis for the majority of pediatric patients with urticaria pigmentosa is extremely good, and over half of cases clear completely by adolescence, while those with aggressive systemic mastocytosis or mast cell leukemia show a progressive course, usually with a fatal outcome.
  • [MeSH-major] Mastocytosis, Cutaneous / diagnosis

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Cutaneous mastocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623875.001).
  • [ISSN] 0353-9466
  • [Journal-full-title] Acta clinica Croatica
  • [ISO-abbreviation] Acta Clin Croat
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 17
  •  go-up   go-down


12. Ozer O, Zhao YD, Ostler KR, Akin C, Anastasi J, Vardiman JW, Godley LA: The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells. Leuk Lymphoma; 2008 Aug;49(8):1567-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells.
  • Mast cell leukemia (MCL) is the most aggressive mast cell neoplasm, but has not been well studied due to its rarity.
  • We identified novel KIT transcripts in two patients with MCL and two patients with SM with an associated hematological disorder, but not from two patients with SM.
  • Similar novel KIT transcripts were also observed in normal CD34+ cells from bone marrow and umbilical cord blood, suggesting that altered KIT isoforms may be specific to the blast stage of hematopoietic precursors.
  • [MeSH-major] Hematopoietic Stem Cells / chemistry. Mastocytosis / genetics. Proto-Oncogene Proteins c-kit / genetics. RNA, Messenger / genetics
  • [MeSH-minor] Adenosine Triphosphate. Alternative Splicing. Antigens, CD34. Binding Sites. Humans. Leukemia, Mast-Cell / genetics. Mastocytosis, Systemic / genetics. Phosphorylation. RNA, Neoplasm / genetics. Sequence Deletion

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2008 Aug;49(8):1431-2 [18766958.001]
  • (PMID = 18766971.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 8L70Q75FXE / Adenosine Triphosphate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


13. Tuohy JL, Milgram J, Worley DR, Dernell WS: A review of sentinel lymph node evaluation and the need for its incorporation into veterinary oncology. Vet Comp Oncol; 2009 Jun;7(2):81-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Being the first lymph node or nodes to which many primary tumours reliably drain, the disease status of the sentinel lymph node/s (SLN) is important in the prediction of survival.
  • Given the prognostic importance of lymph node involvement in tumours such as mammary gland carcinoma, osteosarcoma, synovial cell sarcoma and mast cell tumours, SLN evaluation should be incorporated into routine clinical practice so as to improve our clinical assessment of veterinary oncologic patients.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Staging / veterinary. Neoplasms / veterinary. Sentinel Lymph Node Biopsy / veterinary. Veterinary Medicine
  • [MeSH-minor] Animals. Lymphatic Metastasis. Medical Oncology. Neoplasm Invasiveness. Prognosis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453362.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 82
  •  go-up   go-down


14. Ohashi E, Miyajima N, Nakagawa T, Takahashi T, Kagechika H, Mochizuki M, Nishimura R, Sasaki N: Retinoids induce growth inhibition and apoptosis in mast cell tumor cell lines. J Vet Med Sci; 2006 Aug;68(8):797-802
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoids induce growth inhibition and apoptosis in mast cell tumor cell lines.
  • To investigate the antitumor effect of retinoids on mast cell tumors (MCT), inhibitory effect on cell growth and induction of apoptosis were examined in vitro.
  • Although sensitivity of these cells differed among the cells, the growth of three MCT cell lines (CoMS, CM-MC and VI-MC) were inhibited dose dependently when they were treated with retinoids.
  • FACS analysis of PI-stained nuclei revealed an apoptotic fraction in CM-MC cells about 30% when treated with retinoids, while those of control cells were less than 5%.
  • Caspase-3 activation was observed after retinoid treatment in CM-MC cells.
  • Both retinoid receptors, RARs and RXRs, were detected by immunoprecipitation followed by western blot analysis in all the three MCT cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16953078.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Retinoic Acid; 0 / Retinoids; EC 3.4.22.- / Caspases
  •  go-up   go-down


15. Turin L, Acocella F, Stefanello D, Oseliero A, Fondrini D, Brizzola S, Riva F: Expression of c-kit proto-oncogene in canine mastocytoma: a kinetic study using real-time polymerase chain reaction. J Vet Diagn Invest; 2006 Jul;18(4):343-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit proto-oncogene in canine mastocytoma: a kinetic study using real-time polymerase chain reaction.
  • KIT receptor, the c-kit gene product, is thought to play a major role in canine mastocytoma, one of the most common neoplastic diseases in dogs.
  • In the present study, the expression of c-kit proto-oncogene in blood and in tumor biopsies from 41 dogs with histologically confirmed mastocytoma at different grades of cellular differentiation and 5 negative control dogs was investigated using real-time (quantitative) reverse transcription-polymerase chain reaction (RRT-PCR).
  • The animals were followed up for over 1 year after surgery in order to characterize the kinetics of c-kit expression in blood.
  • Transcript mRNAs extracted from blood at different time points after surgery and from tumor tissue surgically removed from each dog were used in a quantitative RRT-PCR assay targeting the extracellular coding region of the c-kit gene.
  • Levels of expression of c-kit were higher in tumor biopsies than in blood; the blood level decreased in the patients between 1 and 3 months after surgery.
  • No KIT expression was detected in blood from the 5 dogs not affected by mastocytoma (negative controls).
  • The RRT-PCR appears to be a suitable method for sensitive and quantitative detection of c-kit gene expression in canine blood and neoplastic tissues.
  • Although c-kit expression levels measured by RRT-PCR do not correlate with prognosis, they confirm that surgery remains the main treatment to reduce circulating mastocytes and that circulating mast cells can be detected even in benign highly differentiated forms of mastocytoma such as grade I.
  • [MeSH-major] Dog Diseases / genetics. Gene Expression Regulation, Neoplastic. Mastocytoma / veterinary. Polymerase Chain Reaction / veterinary. Proto-Oncogene Proteins c-kit / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921872.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


16. Lin TY, Rush LJ, London CA: Generation and characterization of bone marrow-derived cultured canine mast cells. Vet Immunol Immunopathol; 2006 Sep 15;113(1-2):37-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generation and characterization of bone marrow-derived cultured canine mast cells.
  • Disorders of mast cells, particularly mast cell tumors (MCTs), are common in dogs.
  • In comparison to humans and mice, little is known regarding the biology of canine mast cells.
  • To facilitate the study of mast cell biology in other species, bone marrow-derived cultured mast cells (BMCMCs) often are used because these represent a ready source of large numbers of cells.
  • We have developed a protocol to successfully generate canine BMCMCs from purified CD34(+) cells.
  • After 5-7 weeks of culture with recombinant canine stem cell factor (rcSCF), greater than 90% of the cell population consisted of mast cells as evidenced by staining with Wright's-Giemsa, as well as production of chymase, tryptase, IL-8 and MCP-1.
  • These cells expressed cell surface markers typical of mast cells including Kit, Fc epsilonRI, CD44, CD45 and CD18/CD11b.
  • Cross-linking of cell surface-bound IgE induced the release of histamine and TNFalpha.
  • In summary, canine BMCMCs possess phenotypic and functional properties similar to mast cells found in vivo.
  • These cells represent a novel, valuable resource for investigating normal canine mast cell biology as well as for identifying factors that lead to mast cell dysregulation in the dog.
  • [MeSH-major] Antigens, CD34 / immunology. Bone Marrow Cells / cytology. Dogs / immunology. Mast Cells / cytology
  • [MeSH-minor] Animals. Chemokine CCL2 / metabolism. Chymases. Female. Flow Cytometry / veterinary. Histamine / metabolism. Histocytochemistry / veterinary. Immunoglobulin E / metabolism. Immunophenotyping / veterinary. Interleukin-8 / metabolism. Male. Serine Endopeptidases / metabolism. Stem Cell Factor / metabolism. Tryptases. beta-N-Acetylhexosaminidases / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HISTAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780961.001).
  • [ISSN] 0165-2427
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Chemokine CCL2; 0 / Interleukin-8; 0 / Stem Cell Factor; 37341-29-0 / Immunoglobulin E; 820484N8I3 / Histamine; EC 3.2.1.52 / beta-N-Acetylhexosaminidases; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.39 / Chymases; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


17. Krick EL, Billings AP, Shofer FS, Watanabe S, Sorenmo KU: Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival. Vet Comp Oncol; 2009 Jun;7(2):130-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival.
  • The purpose of this retrospective cohort study is to describe the association of cytological assessment of lymph node metastasis with survival and tumour grade in dogs with mast cell tumours.
  • Regional lymph node aspirates of 152 dogs diagnosed with a mast cell tumour were reviewed and classified according to specific cytological criteria for staging.
  • 97 dogs (63.8%) had stage I tumours, and 55 (36.2%) had stage II tumours.
  • Stage II dogs had a significantly shorter survival time than dogs with stage I disease (0.8 and 6.2 years, respectively; P < 0.0001).
  • Dogs with grade III mast cell tumours were more likely to have stage II disease (P = 0.004).
  • These results suggest that cytological evaluation of lymph nodes in dogs with mast cell tumours provides useful and valuable clinical information, and the results correlate with tumour grade and outcome thus providing a practical and non-invasive method for staging.
  • [MeSH-major] Dog Diseases / mortality. Dog Diseases / pathology. Lymph Nodes / cytology. Mast-Cell Sarcoma / veterinary. Neoplasm Staging / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453367.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Bernstein JA, Hodgin EC, Holloway HW, Hedlund CS, Storey ES, Hubert JD: Mohs micrographic surgery: a technique for total margin assessment in veterinary cutaneous oncologic surgery. Vet Comp Oncol; 2006 Sep;4(3):151-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a unique horizontal sectioning technique, MMS enables 100% surgical margin assessment and provides the lowest recurrence rates for locally invasive tumours.
  • It was hypothesized that MMS technique could provide 100% tumour margin assessment using frozen and/or formalin-fixed horizontal histopathologic sections.
  • Tumour excision and colour-coded mapping were performed, and specimen tissue was fixed using either frozen sections or formalin-fixed sections.
  • Horizontal sections were assessed for quality and presence and location of neoplastic cells based on the mapped orientation.
  • The MMS technique was used in the excision of six squamous cell carcinomas and five mast cell tumours.
  • In all cases, the MMS permitted 100% tumour margins examination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754812.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Horny HP, Sotlar K, Valent P: Mastocytosis: state of the art. Pathobiology; 2007;74(2):121-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mastocytosis is a neoplastic disease involving mast cells (MC) and their CD34+ progenitors.
  • (1) Cutaneous mastocytosis (CM), a benign disease in which MC infiltration is confined to the skin, is preferentially seen in young children and exhibits a marked tendency to regress spontaneously. (2) Systemic mastocytosis (SM) which is commonly diagnosed in adults and includes four major subtypes: (i) indolent SM (ISM, the most common form involving mainly skin and bone marrow);.
  • (ii) a unique subcategory termed SM with an associated non-mast cell clonal hematological disease (SM-AHNMD);.
  • (iii) aggressive SM usually presenting without skin lesions, and (iv) MC leukemia, probably representing the rarest variant of human leukemias. (3) The extremely rare localized extracutaneous MC neoplasms, either presenting as malignancy (MC sarcoma) or as benign tumor termed extracutaneous mastocytoma.
  • To establish the diagnosis of SM, at least one major and one minor criterion, or at least three minor criteria, have to be fulfilled.
  • Most patients, in particular those with CM and ISM, remain in an indolent stage over many years or even decades, while others, in particular those with aggressive SM, SM-AHNMD, or mast cell leukemia, show a progressive course, usually with a fatal outcome.
  • [MeSH-major] Bone Marrow / pathology. Mast Cells / pathology. Mastocytosis / diagnosis. Skin / pathology
  • [MeSH-minor] Antigens, CD2 / analysis. Antigens, CD34 / analysis. Biopsy. Diagnosis, Differential. Disease Progression. Humans. Interleukin-2 Receptor alpha Subunit / analysis. Leukemia, Mast-Cell / diagnosis. Leukemia, Mast-Cell / pathology. Mast-Cell Sarcoma / diagnosis. Mast-Cell Sarcoma / pathology. Mastocytosis, Cutaneous / diagnosis. Mastocytosis, Cutaneous / pathology. Mastocytosis, Systemic / diagnosis. Mastocytosis, Systemic / pathology. Mutation. Practice Guidelines as Topic. Prognosis. Proto-Oncogene Proteins c-kit / analysis. Proto-Oncogene Proteins c-kit / genetics. Tryptases / analysis. World Health Organization

  • Genetic Alliance. consumer health - Mast cell disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587883.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD2; 0 / Antigens, CD34; 0 / Interleukin-2 Receptor alpha Subunit; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.21.59 / Tryptases
  • [Number-of-references] 62
  •  go-up   go-down


20. Cartier D, Jégou S, Parmentier F, Lihrmann I, Louiset E, Kuhn JM, Bastard C, Plouin PF, Godin M, Vaudry H, Lefebvre H: Expression profile of serotonin4 (5-HT4) receptors in adrenocortical aldosterone-producing adenomas. Eur J Endocrinol; 2005 Dec;153(6):939-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In situ hybridization studies showed that 5-HT4 receptor mRNAs were expressed in both zona glomerulosa and zona fasciculata/reticularis of the normal cortex and in groups of APA steroidogenic cells disseminated in the tumor tissues.
  • Immunohistochemical studies revealed the presence of 5-HT-immunoreactivity in both mast cells and clusters of steroidogenic cells in APA tissues.
  • They also demonstrate the presence of 5-HT in both mast cells and tumor steroidogenic cells, providing evidence for a possible autocrine/paracrine activation of aldosterone secretion within adenoma tissues.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322401.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 158165-40-3 / Receptors, Serotonin, 5-HT4; 4964P6T9RB / Aldosterone
  •  go-up   go-down


21. Finora K, Leibman NF, Fettman MJ, Powers BE, Hackett TA, Withrow SJ: Cytological comparison of fine-needle aspirates of liver and spleen of normal dogs and of dogs with cutaneous mast cell tumours and an ultrasonographically normal appearing liver and spleen. Vet Comp Oncol; 2006 Sep;4(3):178-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological comparison of fine-needle aspirates of liver and spleen of normal dogs and of dogs with cutaneous mast cell tumours and an ultrasonographically normal appearing liver and spleen.
  • Staging of dogs with cutaneous mast cell tumours (MCTs) is an important diagnostic step.
  • This study cytologically compared mast cell numbers in fine-needle aspirates of liver and spleen of clinically normal unaffected dogs with those of dogs with cutaneous MCT and an ultrasonographically normal appearing liver and spleen.
  • For splenic aspirates, affected dogs showed significantly more mast cells per cluster (P = 0.04) and more isolated mast cells per slide (P = 0.03) compared with unaffected dogs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754814.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Mederle O, Mederle N, Bocan EV, Ceauşu R, Raica M: VEGF expression in dog mastocytoma. Rev Med Chir Soc Med Nat Iasi; 2010 Jan-Mar;114(1):185-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF expression in dog mastocytoma.
  • The biologic behavior of mastocytomas is highly variable; some tumors have a benign behavior, whereas others exhibit aggressive growth and metastasis.
  • Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis and a potential autocrine growth factor for neoplastic cells in various malignancies.
  • MATERIAL AND METHOD: In the present study, we have investigated expression of VEGF in cutaneous tumor from a dog and combined immunohistochemical expression of VEGF with mast cell tryptase, CD117 and vimentin.
  • RESULTS: Tumor cells were positive for VEGF, and inflammatory cells were negative.
  • VEGF expression was found in tumor cells as a heterogeneous positive reaction, with cytoplasmic pattern and moderate to strong in intensity.
  • Arrangement of tumor cells was in clusters, in deepest part, close to the proliferation front.
  • The dog died 5 month from the diagnosis, and our observation suggest that VEGF secretion by tumor cells correlates with unfavorable prognosis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Dog Diseases / metabolism. Mastocytoma / veterinary. Skin Neoplasms / veterinary. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20509299.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0 / Vimentin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


23. Reiter E, Azzi A, Zingg JM: Enhanced anti-proliferative effects of combinatorial treatment of delta-tocopherol and resveratrol in human HMC-1 cells. Biofactors; 2007;30(2):67-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced anti-proliferative effects of combinatorial treatment of delta-tocopherol and resveratrol in human HMC-1 cells.
  • Here we wanted to determine whether the combined treatment of mast cells with the two compounds inhibits cell proliferation more efficiently when compared to individual treatments.
  • Both compounds inhibit HMC-1 mastocytoma cell proliferation and reduce the activity of Protein Kinase B (PKB/Akt) by inhibiting its Ser473-phosphorylation.
  • The combination of 50 microM delta-tocopherol and 50 microM resveratrol inhibits proliferation of HMC-1 cells more efficiently when compared to single treatments.
  • Our data suggest that delta-tocopherol and resveratrol can act additively in reducing cell proliferation and PKB phosphorylation.
  • The combination of phytochemicals with relatively broad specificity on enzymes involved in signal transduction and gene expression may increase their activity in disease prevention by modulating several different molecular targets.
  • [MeSH-major] Cell Division / drug effects. Stilbenes / pharmacology. Tocopherols / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Drug Interactions. Enzyme Inhibitors / pharmacology. Humans. Mast Cells / drug effects. Mastocytoma. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. alpha-Tocopherol / pharmacology. beta-Tocopherol / pharmacology. gamma-Tocopherol / pharmacology

  • Hazardous Substances Data Bank. RESVERATROL .
  • Hazardous Substances Data Bank. VITAMIN E .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356579.001).
  • [ISSN] 0951-6433
  • [Journal-full-title] BioFactors (Oxford, England)
  • [ISO-abbreviation] Biofactors
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Stilbenes; 1406-66-2 / Tocopherols; 8EF1Z1238F / gamma-Tocopherol; 9U6A490501 / beta-Tocopherol; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; H4N855PNZ1 / alpha-Tocopherol; JU84X1II0N / delta-tocopherol; Q369O8926L / resveratrol
  •  go-up   go-down


24. Rebuzzi L, Willmann M, Sonneck K, Gleixner KV, Florian S, Kondo R, Mayerhofer M, Vales A, Gruze A, Pickl WF, Thalhammer JG, Valent P: Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol; 2007 Feb 15;115(3-4):320-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells.
  • Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis and a potential autocrine growth factor for neoplastic cells in various malignancies.
  • In the present study, we have investigated expression of VEGF and VEGF receptors in canine mastocytomas and the canine mastocytoma cell line C2.
  • As assessed by immunostaining of tissue sections and cytospin slides, primary neoplastic mast cells (MC) and C2 cells were found to express the VEGF protein.
  • In Northern blot and RT-PCR experiments, C2 cells expressed VEGF mRNA in a constitutive manner.
  • VEGF mRNA expression in C2 cells was counteracted by LY294002 and rapamycin, suggesting involvement of the PI3-kinase/mTOR pathway.
  • Moreover, C2 cells were found to express VEGF receptor-1 (Flt-1) and VEGF receptor-2 (KDR).
  • However, recombinant VEGF failed to promote (3)H-thymidine uptake in C2 cells, and a neutralizing anti-VEGF antibody (bevacizumab) failed to downregulate spontaneous proliferation in these cells.
  • In addition, rapamycin decreased the expression of VEGF in C2 cells at the mRNA and protein level without suppressing their proliferation.
  • Together, canine mastocytoma cells express VEGF as well as VEGF receptors.
  • However, despite co-expression of VEGF and its receptors, VEGF is not utilized as an autocrine growth regulator by canine mastocytoma cells.
  • [MeSH-major] Dog Diseases / metabolism. Mastocytoma / veterinary. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor Receptor-1 / biosynthesis. Vascular Endothelial Growth Factor Receptor-2 / biosynthesis
  • [MeSH-minor] Animals. Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Bevacizumab. Blotting, Northern / veterinary. Cell Line, Tumor. Chromones / pharmacology. Dogs. Female. Flavonoids / pharmacology. Flow Cytometry / veterinary. Immunohistochemistry / veterinary. Male. Morpholines / pharmacology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / metabolism. Protein Kinase Inhibitors / pharmacology. RNA / chemistry. RNA / genetics. Reverse Transcriptase Polymerase Chain Reaction / veterinary. Sirolimus / pharmacology

  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196258.001).
  • [ISSN] 0165-2427
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Chromones; 0 / Flavonoids; 0 / Morpholines; 0 / Protein Kinase Inhibitors; 0 / Vascular Endothelial Growth Factor A; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 2S9ZZM9Q9V / Bevacizumab; 63231-63-0 / RNA; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


25. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM: Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res; 2009 Jun 1;15(11):3856-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
  • PURPOSE: The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell tumors (MCT) with toceranib phosphate (Palladia, SU11654), a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRbeta.
  • Secondary objectives were to determine biological response rate, time to tumor progression, duration of objective response, health-related quality of life, and safety of Palladia.
  • The ORR for all 145 dogs receiving Palladia was 42.8% (21 complete response, 41 partial response); among the 62 responders, the median duration of objective response and time to tumor progression was 12.0 weeks and 18.1 weeks, respectively.
  • This clinical trial further shows that spontaneous tumors in dogs are good models to evaluate therapeutic index of targeted therapeutics in a clinical setting.
  • [MeSH-major] Dog Diseases / drug therapy. Indoles / therapeutic use. Mast-Cell Sarcoma / drug therapy. Pyrroles / therapeutic use. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • [MeSH-minor] Animals. Anorexia / chemically induced. Diarrhea / chemically induced. Disease Progression. Dogs. Female. Male. Neoplasm Recurrence, Local. Random Allocation. Treatment Outcome. Vomiting / chemically induced

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2009 Jun 1;15(11):3645-7 [19470723.001]
  • (PMID = 19470739.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Pyrroles; 24F9PF7J3R / toceranib phosphate; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


26. Riva F, Brizzola S, Stefanello D, Crema S, Turin L: A study of mutations in the c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest; 2005 Jul;17(4):385-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of mutations in the c-kit gene of 32 dogs with mastocytoma.
  • Mutations in the intracellular juxtamembrane domain of the c-kit gene in 32 dogs with different grades of histologically confirmed mastocytoma were studied.
  • The region corresponding to the c-kit juxtamembrane domain was sequenced and compared with GenBank sequences.
  • The c-kit juxtamembrane domain sequences of all dogs were grouped in 3 clusters.
  • No mutations were detected in tissues constitutively expressing c-kit (cerebellum and spleen), obtained from dogs not affected by mastocytoma (controls).
  • All the substitutions were found in dogs bearing grade I or II mast cell tumors; the deletion was detected in 1 dog with grade II mastocytoma.
  • [MeSH-major] Dog Diseases / genetics. Mastocytoma / veterinary. Mutation. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Animals. Base Sequence. Dogs. Female. Male. Molecular Sequence Data. Oncogenes. Polymerase Chain Reaction / veterinary. RNA, Neoplasm / chemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16131001.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


27. Thamm DH, Turek MM, Vail DM: Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci; 2006 Jun;68(6):581-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases.
  • The medical records of 61 dogs with MCT at high risk for metastasis that were treated with prednisone and VBL following excision+/-radiation therapy were reviewed, and median disease-free interval (DFI), median overall survival time (OS) and prognostic factors assessed.
  • High-grade and mucocutaneous tumors had a worse outcome, and the use of prophylactic nodal irradiation appeared to improve outcome in this group of dogs.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820715.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5V9KLZ54CY / Vinblastine; VB0R961HZT / Prednisone
  •  go-up   go-down


28. Fulciniti F, Di Mattia D, Curcio MP, Bove P, Rota AM, Botti G: Canine mastocytoma: report of 8 cases diagnosed by fine needle cytology and clinicopathologic correlations. Acta Cytol; 2007 Jul-Aug;51(4):616-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine mastocytoma: report of 8 cases diagnosed by fine needle cytology and clinicopathologic correlations.
  • BACKGROUND: Mast cell proliferations are commoner in dogs than in humans; mass forming lesions in the former are apt to fine needle sampling and the obtained cytopathological picture might be informing to enhance recognition of similar proliferations in humans.
  • CASE: Clinical and cytopathologic data were collected from 8 cases of canine mastocytomas diagnosed by fine needle cytology.
  • In all cases the cytopathological diagnosis was confirmed by histopathologic examination of the excised mass, by necropsy or by response to therapy.
  • CONCLUSION: There are marked similarities between canine and human mastocytomas, despite possible differences in the clinical course of the disease in both species.
  • Canine mastocytomas may hence be used as an animal model of a human disease and, as such, familiarity with their cytologic presentation may be useful for recognizing mast cell proliferations in humans.
  • [MeSH-major] Dog Diseases / diagnosis. Dog Diseases / pathology. Mastocytoma / diagnosis. Mastocytoma / veterinary
  • [MeSH-minor] Animals. Biopsy, Fine-Needle. Dogs. Female. Immunohistochemistry. Immunophenotyping. Lymph Nodes / pathology. Male. Mast Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718137.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Seledtsov VI, Seledtsova GV, Samarin DM, Senyukov VV, Poveschenko OV, Felde MA, Kozlov VA: Erythroid cells in suppressing leukemia cell growth. Leuk Lymphoma; 2005 Sep;46(9):1353-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythroid cells in suppressing leukemia cell growth.
  • This paper indicates that murine nucleated erythroid cells (EC) are able to reduce, in a dose-dependent manner, the proliferation of both L1210 lymphoma and P815 mastocytoma cells and that the leukemia cell growth inhibitory activity of unseparated bone marrow (BM) cells may be markedly augmented by their short-term culturing with erythropoietin (Epo).
  • These results raise the intriguing possibility to utilize erythropoesis-stimulating, therapeutic strategies with the purpose of inhibiting leukemia cell growth in the body.
  • [MeSH-major] Erythroid Cells / cytology. Leukemia, Experimental / pathology
  • [MeSH-minor] Animals. Bone Marrow Cells / physiology. Cell Division / drug effects. Cells, Cultured. Erythropoietin / pharmacology. Leukemia L1210 / pathology. Mice. Mice, Inbred Strains. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109614.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11096-26-7 / Erythropoietin
  •  go-up   go-down


30. Spugnini EP, Vincenzi B, Baldi F, Citro G, Baldi A: Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors. Anticancer Res; 2006 Nov-Dec;26(6B):4585-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors.
  • The purpose of this investigation was to assess the adjuvant potentials of ECT for the treatment of incompletely excised mast cell tumors (MCT).
  • Three dogs died of metastatic disease that they developed at the same time of local recurrence, one developed multiple cutaneous nodules at different locations and one with recurrence was re-treated and is currently disease-free after 22 months.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Dog Diseases / therapy. Electric Stimulation Therapy. Mastocytoma / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17201181.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


31. Northrup NC, Harmon BG, Gieger TL, Brown CA, Carmichael KP, Garcia A, Latimer KS, Munday JS, Rakich PM, Richey LJ, Stedman NL, Cheng AL, Howerth EW: Variation among pathologists in histologic grading of canine cutaneous mast cell tumors. J Vet Diagn Invest; 2005 May;17(3):245-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation among pathologists in histologic grading of canine cutaneous mast cell tumors.
  • Ten veterinary pathologists at 1 veterinary institution independently assigned histologic grades to the same 60 canine cutaneous mast cell tumors (MCTs).
  • [MeSH-major] Dog Diseases / pathology. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15945380.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Wobeser BK, Kidney BA, Powers BE, Withrow SJ, Mayer MN, Spinato MT, Allen AL: Diagnoses and clinical outcomes associated with surgically amputated feline digits submitted to multiple veterinary diagnostic laboratories. Vet Pathol; 2007 May;44(3):362-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eighty-five separate submissions were reviewed for diagnosis, age, sex, limb of origin, and digits affected; and the original submitting clinics were surveyed to determine clinical outcome.
  • The Kaplan-Meier product-limit method was used to determine the disease-free interval and survival time.
  • Neoplastic disease was identified in 63 of 85 submissions, with exclusively inflammatory lesions composing the other 22 cases.
  • In 60 (95.2%) of the neoplastic cases, a malignant tumor was identified.
  • Squamous cell carcinoma was the most commonly identified malignant tumor (n = 15; 23.8%) and was associated with a median survival time of 73 days.
  • Other diagnoses included fibrosarcoma (n = 14; 22.2%); adenocarcinoma, likely metastases of a primary pulmonary neoplasm (n = 13; 20.6%); osteosarcoma (n = 5; 7.9%); mast cell tumor (n = 4; 6.3%); hemangiosarcoma (n = 5; 7.9%); malignant fibrous histiocytoma (n = 2; 3.2%); giant cell tumor of bone (n = 2; 3.2%); and hemangioma (n = 2; 3.2%).
  • Giant cell tumor of bone has not been previously described in the digits of cats.
  • Various neoplasms can occur in the digits of cats, and submission of the amputated digit for histopathologic diagnosis is essential to determine the histogenesis and predict the clinical outcome.
  • [MeSH-major] Amputation / veterinary. Cat Diseases / diagnosis. Foot Diseases / veterinary. Inflammation / veterinary. Neoplasms / veterinary


33. Roskoski R Jr: Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor. Biochem Biophys Res Commun; 2005 Nov 11;337(1):1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
  • Signaling by stem cell factor and Kit, its receptor, plays important roles in gametogenesis, hematopoiesis, mast cell development and function, and melanogenesis.
  • Moreover, human and mouse embryonic stem cells express Kit transcripts.
  • Stem cell factor exists as both a soluble and a membrane-bound glycoprotein while Kit is a receptor protein-tyrosine kinase.
  • The complete absence of stem cell factor or Kit is lethal.
  • Deficiencies of either produce defects in red and white blood cell production, hypopigmentation, and sterility.
  • Gain-of-function mutations of Kit are associated with several human neoplasms including acute myelogenous leukemia, gastrointestinal stromal tumors, and mastocytomas.
  • Binding of stem cell factor to Kit results in receptor dimerization and activation of protein kinase activity.


34. Poirier VJ, Adams WM, Forrest LJ, Green EM, Dubielzig RR, Vail DM: Radiation therapy for incompletely excised grade II canine mast cell tumors. J Am Anim Hosp Assoc; 2006 Nov-Dec;42(6):430-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy for incompletely excised grade II canine mast cell tumors.
  • Forty-five dogs with incompletely excised grade II mast cell tumors were treated with radiation using a cobalt 60 teletherapy unit (15 fractions of 3.2 Gy for a total of 48 Gy).
  • Three (6.7%) dogs had tumor recurrence, two (4.4%) dogs developed metastasis, and 14 (31%) dogs developed a second cutaneous mast cell tumor.
  • [MeSH-major] Cobalt Isotopes / therapeutic use. Dog Diseases / radiotherapy. Mastocytoma / veterinary. Radioisotope Teletherapy / veterinary
  • [MeSH-minor] Animals. Dogs. Female. Kaplan-Meier Estimate. Lymph Nodes / radiation effects. Lymphatic Metastasis / prevention & control. Male. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / veterinary. Retrospective Studies. Severity of Illness Index. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088389.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cobalt Isotopes
  •  go-up   go-down


35. Kleinschmidt S, Harder J, Nolte I, Marsilio S, Hewicker-Trautwein M: Chronic inflammatory and non-inflammatory diseases of the gastrointestinal tract in cats: diagnostic advantages of full-thickness intestinal and extraintestinal biopsies. J Feline Med Surg; 2010 Feb;12(2):97-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An evaluation of histological findings in full-thickness biopsies from the gastrointestinal tract (GIT) and extraintestinal samples of 43 cats with chronic GIT disease signs was performed.
  • In the majority of cases (46.5%) inflammatory bowel disease, ie, lymphocytic-plasmacytic enteritis/colitis (32.6%), eosinophilic gastroenterocolitis (11.6%) and mixed inflammatory infiltration (2.3%), was diagnosed.
  • In two cats a mast cell tumour (4.7%) was diagnosed.
  • The availability of transmural biopsies from all segments of the intestine and the collection of extraintestinal samples, especially mesenteric lymph nodes, is especially helpful for diagnosing intestinal tumours such as lymphomas and tumours of mast cell origin.
  • [MeSH-minor] Animals. Cats. Chronic Disease. Diagnosis, Differential. Female. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / veterinary. Liver / pathology. Lymph Nodes / pathology. Male. Pancreas / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Biopsy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 ESFM and AAFP. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19664949.001).
  • [ISSN] 1532-2750
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Jacobi S, Stanley BJ, Petersen-Jones S, Dervisis N, Dominguez PA: Use of an axial pattern flap and nictitans to reconstruct medial eyelids and canthus in a dog. Vet Ophthalmol; 2008 Nov-Dec;11(6):395-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 10-year-old male neutered Boxer presented with recurrence of a mast cell tumor at the right medial canthal area.
  • [MeSH-major] Dog Diseases / surgery. Eyelid Neoplasms / veterinary. Eyelids / surgery. Mast-Cell Sarcoma / veterinary. Reconstructive Surgical Procedures / veterinary. Surgical Flaps / veterinary

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046281.001).
  • [ISSN] 1463-5224
  • [Journal-full-title] Veterinary ophthalmology
  • [ISO-abbreviation] Vet Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Xu P, Okkeri J, Hanisch S, Hu RY, Xu Q, Pomorski TG, Ding XY: Identification of a novel mouse P4-ATPase family member highly expressed during spermatogenesis. J Cell Sci; 2009 Aug 15;122(Pt 16):2866-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a novel mouse P4-ATPase family member highly expressed during spermatogenesis.
  • In mouse testis, FetA protein is detected in gamete cells, from pachytene spermatocytes to mature sperms, and its intracellular localization is tightly related with acrosome formation, a process that involves intensive intracellular vesicle formation and fusion.
  • Furthermore, loss-of-function of FetA by RNA interference in mastocytoma P815 cells profoundly perturbs the structural organization of the Golgi complex and causes loss of constitutive secretion at lower temperature.
  • Our findings point to an essential role of FetA in Golgi morphology and secretory function, suggesting a crucial role for this novel murine P4-ATPase in spermatogenesis.
  • [MeSH-minor] Amino Acid Sequence. Animals. Biological Transport. Cell Line, Tumor. Endocytosis. Gene Deletion. Gene Expression Profiling. Gene Expression Regulation, Developmental. Golgi Apparatus / enzymology. Golgi Apparatus / pathology. Golgi Apparatus / ultrastructure. Lipid Metabolism. Male. Mastocytoma / enzymology. Mastocytoma / pathology. Mice. Molecular Sequence Data. Organ Specificity. Phylogeny. RNA, Messenger / genetics. RNA, Messenger / metabolism. Saccharomyces cerevisiae / metabolism. Sequence Alignment. Testis / cytology. Testis / embryology. Testis / enzymology


38. Hunter MJ, Iodice MW, Pathak AK, Street MA, Helm BA: Characterization of an early signaling defect following Fc epsilonRI activation in the canine mastocytoma cell line, C2. Mol Immunol; 2009 Mar;46(6):1260-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of an early signaling defect following Fc epsilonRI activation in the canine mastocytoma cell line, C2.
  • A comparison of IgE recognition by cognate receptors expressed on the C2 canine mastocytoma cell line with analogous events in a rat basophilic leukemia cell line transfected with the alpha-chain subunit of the canine high-affinity IgE receptor using flow cytometry show that canine IgE recognizes the alpha-chain of its cognate receptor on both cell lines.
  • Our study confirms the expression of functional IgE receptors in both cell lines, but receptor-mediated signaling in the C2 line only supports the early stages of downstream signaling as shown by the phosphorylation of the gamma-chain and the failure to effect the phosphorylation of Syk.
  • In contrast RBL-2H3 cells respond to sensitization with IgE and challenge with cognate antigen with tyrosine phosphorylation of the gamma-subunits of the receptor complex followed by downstream phosphorylation of Syk and Ca(2+) mobilization, culminating in beta-hexosaminidase release.
  • We propose that the identification of the precise signaling defect in C2 cells will yield useful information regarding the pathway leading to mast cell exocytosis and facilitate the restoration of the complete signaling cascade through complementation of the missing/defective signal transducer since signaling events downstream of Ca(2+) mobilization are intact as demonstrated by beta-hexosaminidase release following non-immunologic stimulation with the calcium ionophore, A23187.
  • [MeSH-major] Mast Cells / physiology. Receptors, IgE / metabolism
  • [MeSH-minor] Animals. Calcimycin / pharmacology. Cell Line, Tumor. Dogs. Exocytosis. Intracellular Signaling Peptides and Proteins / metabolism. Mastocytoma. Phosphorylation. Protein-Tyrosine Kinases / metabolism. Rats. Signal Transduction. beta-N-Acetylhexosaminidases / secretion

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135724.001).
  • [ISSN] 1872-9142
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BBSQ/Q/2005/06706
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Receptors, IgE; 37H9VM9WZL / Calcimycin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


39. Shi G, Mao J, Yu G, Zhang J, Wu J: Tumor vaccine based on cell surface expression of DcR3/TR6. J Immunol; 2005 Apr 15;174(8):4727-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor vaccine based on cell surface expression of DcR3/TR6.
  • Solid-phase TR6 can trigger reverse signaling of LIGHT and FasL expressed on T cells, and lead to T cell costimulation.
  • In this study, we engineered tumor cells to express cell surface TR6 and used these cells as a tumor vaccine.
  • We demonstrated that mastocytoma P815 cells expressing surface TR6 (TR6-P815) effectively augmented the T cells response in vitro and ex vivo in terms of proliferation, as well as IL-2 and IFN-gamma secretion.
  • TR6-P815 cells had reduced tumorigenicity compared with parental P815 cells.
  • When inactivated TR6-P815 cells were employed as a vaccine, they protected the mice from challenge with live parental P815 cells, and eliminated established P815 tumors.
  • The cell surface TR6-based tumor vaccine was also effective against low antigenicity tumors, such as B16 melanoma; co-administration of bacillus Calmette-Guérin further enhanced the vaccine's efficacy.
  • Thus, cell surface TR6 expression is a useful addition to our tumor vaccine arsenal.
  • [MeSH-major] Cancer Vaccines / isolation & purification. Membrane Glycoproteins / immunology. Receptors, Cell Surface / immunology. Receptors, Tumor Necrosis Factor / immunology
  • [MeSH-minor] Animals. Antigens, Neoplasm. Cell Line, Tumor. Cell Membrane / immunology. Female. Humans. Immunologic Factors / administration & dosage. In Vitro Techniques. Lymphocyte Activation. Mice. Mice, Inbred C57BL. Mice, Inbred DBA. Mice, Knockout. Mice, Nude. Neoplasms, Experimental / immunology. Neoplasms, Experimental / therapy. Receptors, Tumor Necrosis Factor, Member 6b. T-Lymphocytes / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814697.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Immunologic Factors; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human
  •  go-up   go-down


40. Mojahidi S, Rakib el M, Sekkak H, Abouricha S, Benchat N, Mousse HA, Zyad A: Synthesis and in-vitro cytotoxic evaluation of novel pyridazin-4-one derivatives. Arch Pharm (Weinheim); 2010 May;343(5):310-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some of these compounds exhibited in-vitro cytotoxic activity with moderate to excellent growth inhibition against the murine P815 mastocytoma cell line.
  • Compound 5b showed an important cytotoxic activity against cell line P815 (IC(50 )= 0.40 microg/mL).
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Pyridazines / chemical synthesis. Pyridazines / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Screening Assays, Antitumor / methods. Mice. Molecular Structure. Structure-Activity Relationship

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222064.001).
  • [ISSN] 1521-4184
  • [Journal-full-title] Archiv der Pharmazie
  • [ISO-abbreviation] Arch. Pharm. (Weinheim)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyridazines
  •  go-up   go-down


41. Rebhun RB, Thamm DH: Multiple distinct malignancies in dogs: 53 cases. J Am Anim Hosp Assoc; 2010 Jan-Feb;46(1):20-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the clinical recognition of multiple distinct types of neoplasia in individual dogs, a detailed description of such cases has not recently been published.
  • Approximately 3% of 1722 dogs that were presented to the oncology service at the Colorado State University Veterinary Medical Center were diagnosed with multiple distinct primary tumors.
  • Dogs with mast cell tumor, malignant melanoma, and thyroid carcinoma were significantly overrepresented and thus more likely to be diagnosed with multiple tumor types.
  • These findings emphasize the importance of thorough, whole-body evaluation for dogs presented with mast cell tumor, malignant melanoma, and thyroid carcinoma.
  • Furthermore, because approximately 33% of dogs that were presented with thyroid tumors were found to have additional distinct tumors, complete staging is justified in all dogs presented with thyroid tumors.
  • [MeSH-major] Dog Diseases / diagnosis. Neoplasms, Multiple Primary / veterinary. Thyroid Neoplasms / veterinary
  • [MeSH-minor] Animals. Dogs. Female. Genetic Predisposition to Disease. Male. Mastocytoma / diagnosis. Mastocytoma / epidemiology. Mastocytoma / etiology. Mastocytoma / veterinary. Melanoma / diagnosis. Melanoma / epidemiology. Melanoma / etiology. Melanoma / veterinary. Multiple Myeloma / diagnosis. Multiple Myeloma / epidemiology. Multiple Myeloma / etiology. Multiple Myeloma / veterinary. Neoplasm Staging / veterinary. Prevalence. Retrospective Studies. Sex Factors

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20045833.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. LeBlanc AK, Jakoby BW, Townsend DW, Daniel GB: 18FDG-PET imaging in canine lymphoma and cutaneous mast cell tumor. Vet Radiol Ultrasound; 2009 Mar-Apr;50(2):215-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18FDG-PET imaging in canine lymphoma and cutaneous mast cell tumor.
  • Positron Emission Tomography (PET) using the glucose analog 2-deoxy-2-[18F]fluoro-D-glucose (18FDG) is a common imaging modality for diagnosis and management of many human malignancies.
  • We evaluated 18FDG-PET in dogs with either multicentric lymphoma (LSA) or cutaneous mast cell tumor (MCT).
  • Both tumors were characterized by avidity for 18FDG.
  • In two dogs, additional sites of mast cell disease were identified with 18FDG-PET that were undetected on physical examination and/or regional lymph node cytology.
  • [MeSH-major] Dog Diseases / radionuclide imaging. Lymphoma / veterinary. Mastocytoma, Skin / veterinary. Neoplasm Staging / veterinary. Positron-Emission Tomography / veterinary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19400472.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


43. Nishikawa H, Kitani S: Tea catechins have dual effect on mast cell degranulation induced by compound 48/80. Int Immunopharmacol; 2008 Sep;8(9):1207-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tea catechins have dual effect on mast cell degranulation induced by compound 48/80.
  • We investigated catechin's effects on intracellular ROS generation in mast cell activation and degranulation.
  • Compound 48/80, receptor mimetic basic secretagogues for mast cell, induced ROS generation dose-dependently with bell-shaped degranulation pattern in canine cutaneous mastocytoma cells (CM-MC).
  • [MeSH-major] Antioxidants / pharmacology. Catechin / pharmacology. Cell Degranulation / drug effects. Mast Cells / drug effects. Tea / chemistry. p-Methoxy-N-methylphenethylamine / antagonists & inhibitors. p-Methoxy-N-methylphenethylamine / pharmacology
  • [MeSH-minor] Animals. Blotting, Western. Calcium / metabolism. Cells, Cultured. Dogs. Dose-Response Relationship, Drug. Hydrogen Peroxide / pharmacology. Phosphorylation. Protein-Tyrosine Kinases / metabolism. Reactive Oxygen Species / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602066.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Reactive Oxygen Species; 0 / Tea; 4091-50-3 / p-Methoxy-N-methylphenethylamine; 8R1V1STN48 / Catechin; BBX060AN9V / Hydrogen Peroxide; EC 2.7.10.1 / Protein-Tyrosine Kinases; SY7Q814VUP / Calcium
  •  go-up   go-down


44. Bellamy F, Bader T, Moussy A, Hermine O: Pharmacokinetics of masitinib in cats. Vet Res Commun; 2009 Dec;33(8):831-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Masitinib is the first veterinary drug recently approved in Europe to treat mast cell tumours in dogs (Hahn et al. JVIM, Masivet).
  • C-kit is a tyrosine kinase receptor that plays a critical role in the biology of mast cells including differentiation, survival, migration and cytokine/mediator release.
  • Mast cells are involved in a number of allergy-and immune-related diseases in cats such as asthma (Reinero Carol et al.
  • Vet Immunol Immunopathol 121(3-4):9, 2008), inflammatory bowel disease, (Janeczko et al.
  • Vet Mic 128(1-2):15, 2008), and feline mast cell tumours (Rassnick et al.
  • Here, we report the results of a preliminary pharmacokinetic study of masitinib in cats which showed a good bioavailability of ~60% in both sexes.
  • [MeSH-minor] Animals. Biological Availability. Cats. Dogs. Female. Injections, Intravenous / veterinary. Male. Mast Cells / drug effects. Proto-Oncogene Proteins c-kit / antagonists & inhibitors. Rats. Thiazoles / administration & dosage. Thiazoles / blood. Thiazoles / pharmacokinetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Vet Immunol Immunopathol. 2006 Nov 15;114(1-2):168-72 [16908071.001]
  • [Cites] J Am Vet Med Assoc. 2008 Apr 15;232(8):1200-5 [18412534.001]
  • [Cites] J Small Anim Pract. 1995 Nov;36(11):481-8 [8587322.001]
  • [Cites] J Vet Intern Med. 2008 Nov-Dec;22(6):1301-9 [18823406.001]
  • [Cites] J Vet Intern Med. 2004 Nov-Dec;18(6):816-25 [15638264.001]
  • [Cites] Vet Immunol Immunopathol. 2008 Feb 15;121(3-4):241-50 [17981343.001]
  • [Cites] Curr Drug Targets Inflamm Allergy. 2005 Apr;4(2):177-81 [15853739.001]
  • [Cites] Int Immunopharmacol. 2007 May;7(5):597-603 [17386407.001]
  • [Cites] Vet J. 2007 Nov;174(3):541-53 [17306576.001]
  • [Cites] Vet Microbiol. 2008 Apr 1;128(1-2):178-93 [18054447.001]
  • [Cites] J Feline Med Surg. 2004 Jun;6(3):181-8 [15135355.001]
  • [Cites] J Comp Pathol. 2004 Jul;131(1):61-9 [15144800.001]
  • [Cites] Stem Cells. 2005;23(1):16-43 [15625120.001]
  • (PMID = 19533403.001).
  • [ISSN] 1573-7446
  • [Journal-full-title] Veterinary research communications
  • [ISO-abbreviation] Vet. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Thiazoles; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; M59NC4E26P / masitinib
  •  go-up   go-down


45. van Broekhoven CL, Altin JG: The novel chelator lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA(3)-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulatory signals to T cells. Biochim Biophys Acta; 2005 Oct 15;1716(2):104-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The novel chelator lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA(3)-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulatory signals to T cells.
  • Recent studies indicate that the chelator lipid nitrilotriacetic acid ditetradecylamine (NTA-DTDA) can be used to engraft T cell costimulatory molecules onto tumor cell membranes, potentially circumventing the need for genetic manipulation of the cells for development of cell- or membrane-based tumor vaccines.
  • Also, NTA(3)-DTDA-containing liposomes and plasma membrane vesicles (PMV) engrafted with B7.1-6H and CD40-6H exhibit greater binding to T cells, in vitro and in vivo.
  • Engrafted NTA(3)-DTDA-containing PMV encapsulated cytokines such as IL-2, IL-12, GM-CSF and IFN-gamma, allowing targeted delivery of both antigen and cytokine to T cells, and stimulation of antigen-specific T cell proliferation and cytotoxicity.
  • Importantly, use of B7.1-CD40-engrafted PMV containing IL-2 and IL-12 as a vaccine in DBA/2J mice induced protection against challenge with syngeneic tumor cells (P815 mammary mastocytoma), and regression of established tumors.
  • The results show that stable protein engraftment onto liposomal membranes using NTA(3)-DTDA can be used to simultaneously target associated antigen, costimulatory molecules and cytokines to T cells in vivo, inducing strong anti-tumor responses and immunotherapeutic effect.
  • [MeSH-minor] Animals. Antigens / metabolism. Antigens, CD40 / chemistry. Antigens, CD40 / metabolism. Antigens, CD80 / chemistry. Biosensing Techniques. Cell Membrane / metabolism. Cell Proliferation. Chelating Agents / pharmacology. Cytokines / metabolism. Dose-Response Relationship, Drug. Female. Histidine / chemistry. Interleukin-12 / metabolism. Interleukin-2 / metabolism. Kinetics. Lipids. Lymphocyte Activation. Male. Mice. Mice, Inbred DBA. Models, Chemical. Neoplasm Transplantation. Protein Binding. Recombinant Proteins / chemistry. Temperature. Time Factors. Transfection

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRILOTRIACETIC ACID .
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225839.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amines; 0 / Antigens; 0 / Antigens, CD40; 0 / Antigens, CD80; 0 / Chelating Agents; 0 / Cytokines; 0 / Interleukin-2; 0 / Lipids; 0 / Liposomes; 0 / Recombinant Proteins; 0 / nitrilotriacetic acid ditetradecylamine; 187348-17-0 / Interleukin-12; 4QD397987E / Histidine; KA90006V9D / Nitrilotriacetic Acid
  •  go-up   go-down


46. Groot Kormelink T, Abudukelimu A, Redegeld FA: Mast cells as target in cancer therapy. Curr Pharm Des; 2009;15(16):1868-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cells as target in cancer therapy.
  • A close interaction of cancer cells with their microenvironment is important for their growth and survival.
  • In this respect, the involvement of inflammatory cells in the initiation, promotion and progression of cancer has pointed to new therapeutic opportunities in the treatment of cancer.
  • The main immune cell types implicated in tumor-associated inflammation are macrophages, dendritic cells, lymphocytes, neutrophils, eosinophils and mast cells.
  • Their precise role in intercellular communication, regulation of tumor inflammation, and to what respect this inflammation contributes to tumor development, are not completely understood.
  • Mast cells are key effector cells in allergic diseases, but it has become apparent that they also contribute to other pathologies, including autoimmune diseases and cancer.
  • Activated mast cells can release many pro-angiogenic and tumor growth stimulatory mediators.
  • Increased numbers of mast cells are found in many tumors and it has been shown that the number of tumor infiltrating mast cells correlate with increased intratumoral microvessel density, enhanced tumor growth and tumor invasion, and poor clinical outcome.
  • Therefore, modulating mast cell recruitment, viability, activity, or mediator release patterns at malignant sites can be of importance to control tumor growth.
  • In this review, we will focus on the contribution of mast cells to tumor development and growth and the possibilities to interfere in mast cell activation and proliferation in the therapy of cancer.
  • [MeSH-major] Mast Cells / drug effects. Mast Cells / physiology. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Degranulation / drug effects. Cell Degranulation / physiology. Humans. Inflammation / complications. Inflammation / metabolism. Inflammation / pathology. Models, Biological. Signal Transduction / drug effects. Signal Transduction / physiology. Stem Cell Factor / antagonists & inhibitors. Stem Cell Factor / physiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519429.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Stem Cell Factor
  • [Number-of-references] 183
  •  go-up   go-down


47. Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C: The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol; 2008 Oct;36(10):1266-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
  • The purpose of this study was to evaluate a novel HSP90 inhibitor, STA-9090, against wild-type (WT) and mutant Kit in canine bone marrow-derived cultured mast cells (BMCMCs), malignant mast cell lines, and fresh malignant mast cells.
  • MATERIALS AND METHODS: BMCMCs, cell lines, and fresh malignant mast cells were treated with STA-9090, 17-AAG, and SU11654 and evaluated for loss in cell viability, cell death, alterations in HSP90 and Kit expression/signaling, and Kit mutation.
  • STA-9090 activity was tested in a canine mastocytoma xenograft model.
  • RESULTS: Treatment of BMCMCs, cell lines, and fresh malignant cells with STA-9090 induced growth inhibition, apoptosis that was caspase-3/7-dependent, and downregulation of phospho/total Kit and Akt, but not extracellular signal-regulated kinase (ERK) or phosphoinositide-3 kinase (PI-3K).
  • Loss of Kit cell-surface expression was also observed.
  • Furthermore, STA-9090 exhibited superior activity to 17-AAG and SU11654, and was effective against malignant mast cells expressing either WT or mutant Kit.
  • Lastly, STA-9090 inhibited tumor growth in a canine mastocytoma mouse xenograft model.
  • CONCLUSIONS: STA-9090 exhibits broad activity against mast cells expressing WT or mutant Kit, suggesting it may be an effective agent in the clinical setting against mast cell malignancies.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Hematol. 1999 Apr;27(4):689-97 [10210327.001]
  • [Cites] Vet Immunol Immunopathol. 2006 Dec 15;114(3-4):320-34 [17027994.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):1115; author reply 1115 [15705916.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1078-87 [15718306.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Aug;56(2):126-37 [15841378.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1198-206 [15902298.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2506-12 [15972449.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3312-8 [10955818.001]
  • [Cites] Br J Haematol. 2002 Mar;116(4):744-57 [11886377.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S55-61 [11927289.001]
  • [Cites] Blood. 2002 Jul 15;100(2):585-93 [12091352.001]
  • [Cites] Am J Vet Res. 2002 Sep;63(9):1257-61 [12224856.001]
  • [Cites] Leuk Res. 2002 Nov;26(11):979-84 [12363464.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2755-68 [12855656.001]
  • [Cites] Nature. 2003 Sep 25;425(6956):407-10 [14508491.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5):709-16 [14571418.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5729-34 [14654558.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1078-84 [14551138.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3222-5 [15070706.001]
  • [Cites] Trends Mol Med. 2004 Feb;10(2):47-51 [15106614.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4309-18 [15205346.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 2004;151:1-44 [14740253.001]
  • [Cites] Anticancer Drugs. 2004 Aug;15(7):651-62 [15269596.001]
  • [Cites] J Comp Pathol. 1996 Nov;115(4):399-414 [9004081.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):761-72 [16175177.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):1-13 [16129412.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 23;338(3):1307-15 [16226710.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):473-81 [16397263.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1806-9 [16291592.001]
  • [Cites] Leuk Res. 2006 May;30(5):575-82 [16213582.001]
  • [Cites] Neoplasia. 2006 Feb;8(2):104-11 [16611403.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1197-208 [16731752.001]
  • [Cites] Blood. 2006 Jul 1;108(1):286-91 [16434489.001]
  • [Cites] Vet Immunol Immunopathol. 2006 Sep 15;113(1-2):37-52 [16780961.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):345-51 [16779792.001]
  • [Cites] Nat Biotechnol. 2006 Nov;24(11):1307 [17093460.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6826-35 [17121904.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):3-7 [17208434.001]
  • [Cites] Nat Struct Mol Biol. 2007 Feb;14(2):90-4 [17277798.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1625-9 [17363512.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1775-82 [17363532.001]
  • [Cites] Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S30-4 [17419150.001]
  • [Cites] Nat Chem Biol. 2007 Aug;3(8):498-507 [17603540.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jan;107(2):303 [17351742.001]
  • [Cites] Invest New Drugs. 2006 Nov;24(6):543-6 [16832603.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1369-78 [16923571.001]
  • [Cites] Gastric Cancer. 2006;9(3):235-9 [16952044.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9153-61 [16982758.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):838-9 [10468886.001]
  • (PMID = 18657349.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093807; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCATS NIH HHS / TR / UL1 TR000090; United States / NCI NIH HHS / CA / R01 CA93807
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Primers; 0 / HSP90 Heat-Shock Proteins; 0 / STA 9090; 0 / Triazoles; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ NIHMS522755; NLM/ PMC3837096
  •  go-up   go-down


48. Lamm CG, Stern AW, Smith AJ, Cooper EJ, Ullom SW, Campbell GA: Disseminated cutaneous mast cell tumors with epitheliotropism and systemic mastocytosis in a domestic cat. J Vet Diagn Invest; 2009 Sep;21(5):710-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated cutaneous mast cell tumors with epitheliotropism and systemic mastocytosis in a domestic cat.
  • A biopsy of 1 of the lesions was submitted to the Oklahoma Animal Disease Diagnostic Laboratory for evaluation.
  • Histologically, there were multiple dermal nodules composed of sheets of neoplastic round cells.
  • Multifocally, the neoplastic cells formed multiple small clusters of 3 to 5 cells within the epidermis.
  • Distinct cytoplasmic granules were evident within the neoplastic cells with toluidine blue and Giemsa stains.
  • The neoplastic cells were immunoreactive for c-KIT and lacked immunoreactivity for cluster of differentiation 3 with immunohistochemistry.
  • Based on these findings, multiple epitheliotropic cutaneous mast cell tumors were diagnosed.
  • A complete necropsy revealed sheets of similar neoplastic mast cells within the spleen, liver, and individual cells scattered within the bone marrow.
  • To the authors' knowledge, the present report is the first to describe disseminated cutaneous mast cell tumors with epitheliotropism and systemic mastocytosis in a domestic cat.
  • [MeSH-minor] Animals. Anti-Bacterial Agents / therapeutic use. Cats. Exons. Female. Fetus. Mast Cells / pathology. Mycoses / drug therapy. Mycoses / veterinary. Prednisone / therapeutic use. Proto-Oncogene Proteins c-kit / genetics. RNA, Messenger / genetics. Skin Diseases / drug therapy. Skin Diseases / microbiology. Skin Diseases / pathology. Skin Diseases / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19737771.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / RNA, Messenger; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; VB0R961HZT / Prednisone
  •  go-up   go-down


49. Valentine BA: Survey of equine cutaneous neoplasia in the Pacific Northwest. J Vet Diagn Invest; 2006 Jan;18(1):123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survey of equine cutaneous neoplasia in the Pacific Northwest.
  • Sarcoid, squamous cell carcinoma, melanocytic tumors, papillomas, and mast cell tumors were the most common neoplasms, constituting 87.5% of all cutaneous neoplasms.
  • Sarcoid was most common in paints, quarter horses, and Arabians, and was the only common tumor in donkeys and mules.
  • Mean age at diagnosis of equine sarcoid was 9 years.
  • Squamous cell carcinoma constituted 18.3% of all neoplasms and 5.41% of total equine accessions.
  • Ocular squamous cell carcinoma was most common in paints and quarter horses, and penile/preputial squamous cell carcinoma was most common in appaloosas and quarter horses.
  • The mean age of horses with ocular squamous cell carcinoma (13 years) and squamous cell carcinoma of the skin (15 years) was significantly less (P < 0.5) than that of horses with squamous cell carcinoma of the penis and prepuce (21 years) or vulva, anal, and perianal skin (19 years).
  • Findings suggest that equine sarcoid and squamous cell carcinoma occur more frequently in the Pacific Northwest than in the northeastern United States.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Horse Diseases / epidemiology. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566271.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Bussmann C, Hagemann T, Hanfland J, Haidl G, Bieber T, Novak N: Flushing and increase of serum tryptase after mechanical irritation of a solitary mastocytoma. Eur J Dermatol; 2007 Jul-Aug;17(4):332-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flushing and increase of serum tryptase after mechanical irritation of a solitary mastocytoma.
  • Solitary mastocytomas are infiltrates of mast cells in the upper corium, appearing at any side of the body as brownish-reddish plaques in the first months of life.
  • We conclude that uncontrolled stroking of mastocytomas should be avoided in patients with a systemic reaction in their history, since this case demonstrates that despite its limited size, mechanical irritation of a solitary mastocytoma may induce strong systemic symptoms as witnessed by transient increase of the serum tryptase, which to our knowledge has not been described in the literature before.
  • [MeSH-major] Flushing / etiology. Mastocytoma / blood. Mastocytoma / complications. Tryptases / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17540642.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 3.4.21.59 / Tryptases
  •  go-up   go-down


51. Endicott MM, Charney SC, McKnight JA, Loar AS, Barger AM, Bergman PJ: Clinicopathological findings and results of bone marrow aspiration in dogs with cutaneous mast cell tumours: 157 cases (1999-2002). Vet Comp Oncol; 2007 Mar;5(1):31-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological findings and results of bone marrow aspiration in dogs with cutaneous mast cell tumours: 157 cases (1999-2002).
  • Bone marrow aspiration for routine staging of canine cutaneous mast cell tumour is not consistently performed, and the overall incidence of bone marrow infiltration and predictive value of the complete blood count (CBC) is unknown.
  • This study evaluated a series of 157 dogs presented for cutaneous mast cell tumours in which a CBC and bone marrow aspiration were performed.
  • Factors significantly associated with bone marrow infiltration included increased age, leucocytosis, anaemia, neutrophilia, monocytosis, eosinophilia, thrombocytopenia, being purebred and staging at the time of recurrent or progressive disease.
  • Our study suggests that a bone marrow sample is not indicated for routine staging but maybe indicated for those dogs with mast cell tumours having either an abnormal haemogram (neutrophilia, monocytosis, eosinophilia, basophilia, anaemia and thrombocytopenia) or presenting for tumour regrowth, progression or new occurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754799.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Grant IA, Rodriguez CO, Kent MS, Sfilgoi G, Gordon I, Davis G, Lord L, London CA: A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors. J Vet Intern Med; 2008 Mar-Apr;22(2):388-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
  • BACKGROUND: Few effective drugs are available to treat dogs with locally aggressive or metastatic mast cell disease.
  • HYPOTHESIS: Vinorelbine, a semisynthetic derivative of vinblastine, is an effective drug for the treatment of canine mast cell tumors (MCT).
  • Tumor measurements and CBC were evaluated before and 7 days after treatment.
  • The 3rd dog had microscopic complete response to treatment with stable measurable disease.
  • Twenty other dogs (83%) had stable disease and 1 dog (4%) had progressive disease.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312556.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


53. Moulin D, Donzé O, Talabot-Ayer D, Mézin F, Palmer G, Gabay C: Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine; 2007 Dec;40(3):216-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells.
  • In this study, we demonstrate that IL-33 induces the production of pro-inflammatory mediators in mast cells.
  • IL-33 dose and time-dependently stimulated IL-6 secretion by P815 mastocytoma cells and primary mouse bone marrow-derived mast cells (BMMC).
  • These effects of IL-33 appeared to occur independently of mast cell degranulation, The results of this study show for the first time that IL-33, a novel member of the IL-1 family of cytokines, stimulates the production of pro-inflammatory mediators by mast cells in addition to its effect on T helper 2 responses.
  • [MeSH-major] Inflammation Mediators / immunology. Interleukins / pharmacology. Mast Cells / immunology
  • [MeSH-minor] Animals. Bone Marrow Cells / cytology. Bone Marrow Cells / immunology. Bone Marrow Cells / metabolism. Cell Line. Chemokine CCL2 / biosynthesis. Chemokine CCL2 / immunology. Dose-Response Relationship, Drug. Inflammation / drug therapy. Inflammation / immunology. Inflammation / metabolism. Interleukin-1beta / biosynthesis. Interleukin-1beta / immunology. Interleukin-33. Membrane Proteins / immunology. Membrane Proteins / metabolism. Mice. Prostaglandin D2 / biosynthesis. Prostaglandin D2 / immunology. Protein Binding / immunology. Receptors, Interleukin. Th2 Cells / cytology. Th2 Cells / immunology. Time Factors. Tumor Necrosis Factor-alpha / biosynthesis. Tumor Necrosis Factor-alpha / immunology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023358.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ccl2 protein, mouse; 0 / Chemokine CCL2; 0 / Il1rl1 protein, mouse; 0 / Il33 protein, mouse; 0 / Inflammation Mediators; 0 / Interleukin-1beta; 0 / Interleukin-33; 0 / Interleukins; 0 / Membrane Proteins; 0 / Receptors, Interleukin; 0 / Tumor Necrosis Factor-alpha; RXY07S6CZ2 / Prostaglandin D2
  •  go-up   go-down


54. Takeuchi Y, Fujino Y, Watanabe M, Nakagawa T, Ohno K, Sasaki N, Sugano S, Tsujimoto H: Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines. Vet Immunol Immunopathol; 2010 Oct 15;137(3-4):208-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
  • Several studies indicated that KIT mutation could cause ligand-independent activation of c-Kit receptor in canine mast cell tumor (MCT).
  • The objective of this study was to investigate mechanisms of c-Kit receptor activation in various canine MCT cell lines.
  • Four cell lines, HRMC (derived from cutaneous MCT), VIMC1 (visceral MCT), CoMS1 (visceral MCT) and CMMC1 (cutaneous MCT), were cultured in stem cell factor (SCF, a ligand of c-Kit receptor)-free medium and subjected to analyses of KIT mutation, c-Kit receptor phosphorylation, SCF expression and the effects of SCF stimulation.
  • In addition, the SCF/c-Kit receptor autocrine mechanism was verified in HRMC cells.
  • HRMC cells expressed wild type c-Kit receptor.
  • Both VIMC1 and CoMS1 cells had the same one amino acid (AA) substitution in the extracellular domain of c-Kit receptor.
  • CMMC1 cells had at least three variants of c-Kit receptor such as one AA deletion in the extracellular domain (variant A), one AA substitution in the extracellular domain as well as an internal tandem duplication in the juxtamembrane domain (variant B), and a nonsense mutation (variant C).
  • Both mature and immature forms of c-Kit receptor were observed and the c-Kit receptors were phosphorylated in all cell lines.
  • While both mature and immature forms of c-Kit receptor were substantially phosphorylated in CMMC1 cells, the immature form was slightly phosphorylated in other cell lines.
  • Phosphorylation of c-Kit receptor in HRMC, VIMC1 and CoMS1 cells were enhanced by SCF stimulation whereas no enhancement was observed in CMMC1 cells.
  • There was no effect of SCF stimulation on proliferation of all the cell lines.
  • SCF protein was detectable in only HRMC cells although mRNA expression of SCF was detected in all the cell lines.
  • A tyrosine kinase inhibitor Dasatinib (internal inhibitor) inhibited c-Kit receptor phosphorylation in HRMC cells whereas anti-canine SCF antibody (external inhibitor) had no inhibitory effect.
  • Thus there could be no external SCF/c-Kit receptor autocrine mechanism whereas there could be an internal autocrine mechanism within HRMC cells.
  • The results indicated that consistent c-Kit receptor phosphorylation could be caused by the stimulation with autocrine SCF in HRMC cells while it could be caused by functional mutations of KIT in VIMC1, CoMS1 and CMMC1 cells.
  • As the four canine MCT cell lines had various aberrations associated with c-Kit receptor phosphorylation, KIT mutation and SCF expression, such molecular biological diversity might reflect the different biological behavior in canine MCT.
  • [MeSH-minor] Animals. Cell Line, Tumor. Dogs. Phosphorylation. RNA, Messenger / analysis. Stem Cell Factor / genetics. Stem Cell Factor / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20591500.001).
  • [ISSN] 1873-2534
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Stem Cell Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


55. Duryee MJ, Klassen LW, Jones BL, Willis MS, Tuma DJ, Thiele GM: Increased immunogenicity to P815 cells modified with malondialdehyde and acetaldehyde. Int Immunopharmacol; 2008 Aug;8(8):1112-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased immunogenicity to P815 cells modified with malondialdehyde and acetaldehyde.
  • Aldehyde modified proteins have been associated with the development and/or progression of alcoholic liver disease (ALD).
  • Previous studies have shown that malondialdehyde (MDA) and acetaldehyde (AA) synergistically form a unique adduct (MAA) with soluble proteins, which are capable of inducing cytokine release, T-cell proliferation, and antibody production.
  • The purpose of this study was to determine whether MAA adduction can elicit similar responses to cells using a well-defined tumor model.
  • The mouse mastocytoma P815 tumor cell line was modified with MAA (P815-MAA) or left unmodified (P815) and 10(6) irradiated cells were injected into DBA/2 mice once a week for 5 weeks.
  • Serum was collected and tested for antibody responses to P815 cells and the MAA epitope.
  • Immunization of MAA adducted P815 cells into syngeneic DBA/2 mice induced a strong antibody response to the MAA epitope as determined by ELISA on Alb and MAA-Alb (508 microg/ml and 1092 microg/ml, respectively).
  • In addition, antibody to unmodified P815 cells was detected by fluorescent technique.
  • Mice immunized with P815 cells or PBS showed little or no reactivity to the MAA epitope or P815 cells.
  • Finally, in tumor survival studies the mean survival was 14.25 days in PBS treated mice; 15.75 days with P815 immunized mice and 18.25 days with P815-MAA immunized mice.
  • Therefore, these data strongly suggest that antibody responses are induced by P815 cells modified with MAA adducts.
  • This may be a possible tool to begin looking at how alcohol metabolites potentially modify cells and/or cellular components making them recognizable to the immune system as foreign.
  • It is thought that these studies define a model system that will be useful in assessing antibody and potentially T-cell responses to cells that are modified by MAA.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • Hazardous Substances Data Bank. ACETALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Res Toxicol. 1997 Sep;10(9):978-86 [9305579.001]
  • [Cites] Gastroenterology. 1997 Jul;113(1):265-76 [9207287.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Nov;22(8):1731-9 [9835288.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Dec;22(9):1927-42 [9884135.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Dec;22(9):2118-24 [9884160.001]
  • [Cites] Mol Pharmacol. 1999 Feb;55(2):223-33 [9927612.001]
  • [Cites] Immunol Rev. 2004 Dec;202:96-105 [15546388.001]
  • [Cites] Alcohol Clin Exp Res. 2004 Dec;28(12):1931-8 [15608611.001]
  • [Cites] Int J Immunopathol Pharmacol. 2005 Jan-Mar;18(1):173-82 [15698522.001]
  • [Cites] Mol Pharmacol. 2005 Nov;68(5):1423-30 [16105988.001]
  • [Cites] Hepatology. 2000 Apr;31(4):878-84 [10733543.001]
  • [Cites] Alcohol Clin Exp Res. 2000 Jul;24(7):1103-9 [10924016.001]
  • [Cites] Free Radic Biol Med. 2001 Dec 15;31(12):1533-8 [11744326.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):155-68 [11900991.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):571-9 [12124807.001]
  • [Cites] Int Immunopharmacol. 2003 Oct;3(10-11):1381-99 [12946435.001]
  • [Cites] Semin Liver Dis. 2004 Aug;24(3):273-87 [15349805.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:3145-55 [15353344.001]
  • [Cites] J Exp Med. 1975 Nov 1;142(5):1150-64 [53258.001]
  • [Cites] Gastroenterology. 1977 May;72(5 Pt 1):918-23 [300342.001]
  • [Cites] Gastroenterology. 1979 Nov;77(5):1053-61 [90634.001]
  • [Cites] Clin Exp Immunol. 1980 Apr;40(1):1-7 [6156044.001]
  • [Cites] Gut. 1980 Nov;21(11):955-61 [7450561.001]
  • [Cites] Gut. 1981 Feb;22(2):149-52 [7215946.001]
  • [Cites] Clin Exp Immunol. 1983 Oct;54(1):219-24 [6604608.001]
  • [Cites] Alcohol Clin Exp Res. 1983 Fall;7(4):431-5 [6229193.001]
  • [Cites] Lab Invest. 1984 Mar;50(3):341-7 [6366363.001]
  • [Cites] Arch Biochem Biophys. 1984 Feb 15;229(1):7-14 [6703702.001]
  • [Cites] Liver. 1984 Apr;4(2):117-21 [6610087.001]
  • [Cites] J Immunol. 1987 Jun 15;138(12):4515-23 [3108394.001]
  • [Cites] Hepatology. 1990 May;11(5):850-8 [2112112.001]
  • [Cites] Alcohol Clin Exp Res. 1990 Dec;14(6):893-9 [2088126.001]
  • [Cites] Hepatology. 1992 Mar;15(3):515-24 [1544634.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):203-16 [7678237.001]
  • [Cites] Acta Gastroenterol Belg. 1992 Sep-Dec;55(5-6):450-6 [1288043.001]
  • [Cites] Semin Liver Dis. 1993 May;13(2):183-95 [8393215.001]
  • [Cites] Gastroenterology. 1995 Jan;108(1):201-7 [7806042.001]
  • [Cites] Hepatology. 1996 Apr;23(4):872-80 [8666344.001]
  • [Cites] J Histochem Cytochem. 1996 Sep;44(9):1051-7 [8773571.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):686-92 [9721166.001]
  • (PMID = 18550015.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R01 AA010435-11; United States / NIAAA NIH HHS / AA / R37 AA007818; United States / NIAAA NIH HHS / AA / R37 AA007818-17; United States / NIAAA NIH HHS / AA / AA007818-17; United States / NIAAA NIH HHS / AA / R01 AA010435; United States / NIAAA NIH HHS / AA / AA010435-11
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 187348-17-0 / Interleukin-12; 4Y8F71G49Q / Malondialdehyde; GO1N1ZPR3B / Acetaldehyde
  • [Other-IDs] NLM/ NIHMS56834; NLM/ PMC2518647
  •  go-up   go-down


56. Millward LM, Hamberg A, Mathews J, Machado-Parrula C, Premanandan C, Hurcombe SD, Radin MJ, Wellman ML: Multicentric mast cell tumors in a horse. Vet Clin Pathol; 2010 Sep;39(3):365-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric mast cell tumors in a horse.
  • Direct smears of fluid collected by fine-needle aspiration of subcutaneous fluid from both limbs were highly cellular with a predominance of eosinophils accompanied by numerous, moderately atypical, variably granulated mast cells.
  • The cytologic diagnosis was mast cell tumor (MCT) with prominent eosinophilic infiltration with a differential diagnosis of eosinophilic granuloma.
  • The histologic diagnosis was MCT, and staining with toluidine blue and Luna stains confirmed the presence of mast cells and eosinophils, respectively.
  • In addition, the mast cells strongly expressed CD117.
  • This is the first reported case of cutaneous mast cell neoplasia in a horse in which primary presenting complaints were draining tracts and distal limb subcutaneous edema involving multiple limbs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 American Society for Veterinary Clinical Pathology.
  • (PMID = 20412546.001).
  • [ISSN] 1939-165X
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Litster AL, Sorenmo KU: Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia. J Feline Med Surg; 2006 Jun;8(3):177-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia.
  • Mast cell tumours (MCTs) are relatively common tumours of cats, and are the second most common cutaneous tumours in cats in the USA.
  • While the primary splenic form of the disease is far less common, it is usually associated with more severe clinical signs.
  • Signalment, clinical and survival characteristics of mast cell neoplasia were characterised in 41 cats.
  • The most common tumour location was cutaneous/subcutaneous head and trunk.
  • Stage 1a was the most common tumour stage at first diagnosis (n=20), followed by stage 4 (both stage 4a and stage 4b; n=10).
  • Of 22 cats that underwent excisional biopsy, mast cell neoplasia recurred in four cats during the study period.
  • Three of the 41 cats presented with simultaneous cutaneous and either splenic or lymph node tumours.
  • A comparison between cats with only cutaneous tumours (n=30) and those with tumours involving the spleen or lymph nodes (n=11) showed longer survival times for the cutaneous-only group (P=0.031).
  • Twelve of the 41 cats died of mast cell neoplasia during the study period.
  • When a subgroup of cats with only cutaneous tumours (no lymph node or visceral involvement) were divided according to whether there were multiple (five or more) tumours (n=6) or a single tumour (n=19), cats with single tumours survived longer than those with multiple tumours (P=0.001).
  • Solitary cutaneous feline MCTs without spread to the lymph nodes usually manifest as benign disease with a relatively protracted course.
  • However, multiple cutaneous tumours, recurrent tumours and primary splenic disease should receive a guarded prognosis due to the relatively short median survival times associated with these forms of the disease.
  • [MeSH-major] Cat Diseases / pathology. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Disease-Free Survival. Follow-Up Studies. Neoplasm Staging. Prognosis. Severity of Illness Index. Survival Analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476559.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, Kato R, Kobayashi T, Fujita M, Fujino Y, Setoguchi A, Ono K, Washizu T, Bonkobara M: Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med; 2008 Jul-Aug;22(4):985-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
  • Mutation of c-kit exon 11, which induces constitutive phosphorylation of KIT, is one of the mechanisms for the development or progression of mast cell tumor (MCT) in dogs.
  • HYPOTHESIS: Imatinib mesylate has activity against MCT in dogs, and response to treatment can be correlated to presence of mutation within exon 11 of c-kit.
  • ANIMALS: Twenty-one dogs with MCT with gross tumor burden and median tumor size of 7.2 cm (range, 1.0-25.3 cm) before treatment.
  • METHODS: Tumors were analyzed for mutation of c-kit exon 11.
  • Response could not be predicted based on presence of absence of a mutation in exon 11 of c-kit.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564222.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


59. Maiolino P, Cataldi M, Paciello O, Restucci B, De Vico G: Nucleomorphometric analysis of canine cutaneous mast cell tumours. J Comp Pathol; 2005 Aug-Oct;133(2-3):209-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleomorphometric analysis of canine cutaneous mast cell tumours.
  • Thirty-five canine cutaneous mast cell tumours (CCMCTs) were analysed by computerized nuclear morphometry.
  • In each case, the nuclei of at least 100 neoplastic cells were measured, and the mean nuclear area (MNA), mean nuclear perimeter (MNP) and mean nuclear form factor (FF) were calculated.
  • Significant differences in respect of MNA and MNP occurred between tumours of grades I and III and between those of grades II and III (P<0.01) but not between tumours of grades I and II (P>0.01).
  • No significant differences in respect of FF were observed between tumours of different grades.
  • [MeSH-major] Cell Nucleus / pathology. Dog Diseases / pathology. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Dogs. Female. Male. Neoplasm Recurrence, Local / veterinary. Neoplasm Staging / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045919.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Marconato L, Leo C, Girelli R, Salvi S, Abramo F, Bettini G, Comazzi S, Nardi P, Albanese F, Zini E: Association between waste management and cancer in companion animals. J Vet Intern Med; 2009 May-Jun;23(3):564-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Odds ratio (OR) between high- and low-danger areas was calculated for all tumors and various malignancies in dogs and cats.
  • A 2.39-fold increased risk of lymphoma (P < .01) accounted for the greater tumor frequency in dogs residing in high-danger areas.
  • The risk of mast cell tumor and mammary cancer did not differ in dogs residing in high- or low-danger areas.
  • Thus, epidemiological studies of spontaneous tumors in dogs might suggest a role for environmental factors in canine and human carcinogenesis and can predict health hazards for humans.

  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298612.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants
  •  go-up   go-down


61. Teske E, Kirpensteijn J, Rutteman GR: [A mastocytoma in a dog]. Tijdschr Diergeneeskd; 2007 Feb 15;132(4):122-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A mastocytoma in a dog].
  • [Transliterated title] Het mastocytoom bij de hond.
  • [MeSH-major] Amputation / veterinary. Antineoplastic Agents / therapeutic use. Dog Diseases / pathology. Mastocytoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Dogs. Mast Cells / metabolism. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17366874.001).
  • [ISSN] 0040-7453
  • [Journal-full-title] Tijdschrift voor diergeneeskunde
  • [ISO-abbreviation] Tijdschr Diergeneeskd
  • [Language] dut
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


62. Murphy S, Sparkes AH, Blunden AS, Brearley MJ, Smith KC: Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Vet Rec; 2006 Mar 4;158(9):287-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours.
  • Between 1997 and 1999, 280 dogs with mast cell tumours were identified, of which 59 (21 per cent) had multiple tumours.
  • Follow-up data for survival analysis were available for 145 dogs with single tumours and 50 dogs with multiple tumours.
  • There was no significant difference between the survival times of the two groups; the survival rates after 12 and 24 months were 88 per cent and 83 per cent, respectively, for the dogs with single tumours, and 86 per cent at both intervals for the dogs with multiple tumours.
  • Eight of the dogs with single tumours had lymph node metastases (stage II disease) and these dogs had a median survival time of 431 days, whereas the 50 dogs with multiple tumours (classified as stage III disease) and the dogs with single tumours (classified as stage I disease) had not reached their median survival times.
  • Golden retrievers appeared to be predisposed to developing multiple tumours in the population studied, with an odds ratio of 3.8.
  • This study found no evidence that dogs with multiple tumours had different survival times than those with single tumours, although there was evidence that the presence of lymph node metastasis generally carried a poorer prognosis.
  • [MeSH-major] Dog Diseases / mortality. Dog Diseases / pathology. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Breeding. Dogs. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517820.001).
  • [ISSN] 0042-4900
  • [Journal-full-title] The Veterinary record
  • [ISO-abbreviation] Vet. Rec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI: Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med; 2007 Oct;13(10):1211-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors.
  • Myc is a pleiotropic transcription factor that is overexpressed in many human cancers and instructs many extracellular aspects of the tumor tissue phenotype, including remodeling of tumor stroma and angiogenesis.
  • Here we show in a beta-cell tumor model that activation of Myc in vivo triggers rapid recruitment of mast cells to the tumor site-a recruitment that is absolutely required for macroscopic tumor expansion.
  • In addition, treatment of established beta-cell tumors with a mast cell inhibitor rapidly triggers hypoxia and cell death of tumor and endothelial cells.
  • Inhibitors of mast cell function may therefore prove therapeutically useful in restraining expansion and survival of pancreatic and other cancers.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Mast Cells / metabolism. Neovascularization, Pathologic / etiology. Pancreatic Neoplasms / blood supply. Proto-Oncogene Proteins c-myc / physiology
  • [MeSH-minor] Animals. Bone Marrow Cells / cytology. Cells, Cultured. Chemokine CCL2 / metabolism. Chemokine CCL5 / metabolism. Femur / cytology. Gene Expression Regulation, Neoplastic. Immunohistochemistry. Mice. Mice, Inbred C57BL. Mice, Transgenic. Oligonucleotide Array Sequence Analysis


64. Thappa DM, Jeevankumar B: Solitary mastocytoma. Indian Pediatr; 2005 Apr;42(4):390
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary mastocytoma.
  • [MeSH-major] Mastocytoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876605.001).
  • [ISSN] 0019-6061
  • [Journal-full-title] Indian pediatrics
  • [ISO-abbreviation] Indian Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


65. Matsumoto M, Ikeda M, Takeya M, Kodama H: Plane xanthoma associated with multiple mastocytoma. Pediatr Dermatol; 2007 Sep-Oct;24(5):E66-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plane xanthoma associated with multiple mastocytoma.
  • The brown macules showed infiltration of a large number of mast cells and a small number of scattered foam cells, whereas in the yellowish plaques, the number of foam cells was greatly increased.
  • Immunohistochemical analysis found that the foam cells were stained with monocyte/macrophage markers including HAM56, and with SRA-C6, a monoclonal antibody to macrophage scavenger receptor class A (CD204).
  • Therefore, the yellowish plaques were considered to be plane xanthoma associated with cutaneous mastocytoma.
  • [MeSH-minor] Foam Cells / pathology. Humans. Infant. Male. Mast Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17958784.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Król M, Pawłowski KM, Majchrzak K, Szyszko K, Motyl T: Why chemotherapy can fail? Pol J Vet Sci; 2010;13(2):399-406
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased efflux of drug, enhanced repair/increased tolerance to DNA damage, high antiapoptotic potential, decreased permeability and enzymatic deactivation allow cancer cell survive the chemotherapy.
  • Treatment can lead to the death of most tumor cells (drug-sensitive), but some of them (drug-resistant) survive and grow again.
  • These tumor cells may arise from stem cells.
  • Unfortunately, studies of canine or feline ABC super family members are not as extensive as in human or mice and they are limited to several papers describing PGP in mammary cancer, cutaneous mast cell tumors and lymphoma.
  • The involvement of many different, not fully recognized, mechanisms in multidrug resistance of cancer cells makes the development of effective methods of therapy very difficult.
  • Understanding the mechanisms of drug resistance in cancer cells may improve the results of treatment.
  • This review article provides a synopsis of all aspects that refer to cancer cell resistance to antitumor drugs.
  • [MeSH-minor] Animals. Drug Resistance, Neoplasm. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731201.001).
  • [ISSN] 1505-1773
  • [Journal-full-title] Polish journal of veterinary sciences
  • [ISO-abbreviation] Pol J Vet Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


67. Zhu L, Lang JH, Wang WY: Images for diagnosis. A vulva mastocytoma having grown for eighteen years. Chin Med J (Engl); 2010 Feb 5;123(3):382-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images for diagnosis. A vulva mastocytoma having grown for eighteen years.
  • [MeSH-major] Mastocytoma / diagnosis. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Mastocytosis, Systemic / diagnosis. Mastocytosis, Systemic / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193267.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


68. Horiyama S, Honda C, Suwa K, Umemoto Y, Okada Y, Semma M, Ichikawa A, Takayama M: Sensitive and simple analysis of sorbic acid using liquid chromatography with electrospray ionization tandem mass spectrometry. Chem Pharm Bull (Tokyo); 2008 Apr;56(4):578-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, it is still unclear whether SA and its salts are actually incorporated in these organisms and a higher organisms like mammalian cells.
  • We also show that the method is useful to analyze SA level in the cytosol of mastocytoma cells, which were pretreated with SA.
  • These results suggest the applicability of this method for the highly sensitive determination of SA in the mammalian tissues and cells.
  • [MeSH-minor] Acetates. Cell Differentiation. Cell Line, Tumor. Chromatography, Liquid. Cytosol / chemistry. Humans. Reproducibility of Results. Solvents. Spectrometry, Mass, Electrospray Ionization

  • Hazardous Substances Data Bank. SORBIC ACID .
  • Hazardous Substances Data Bank. AMMONIUM ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379111.001).
  • [ISSN] 0009-2363
  • [Journal-full-title] Chemical & pharmaceutical bulletin
  • [ISO-abbreviation] Chem. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Acetates; 0 / Food Preservatives; 0 / Solvents; RRE756S6Q2 / ammonium acetate; X045WJ989B / Sorbic Acid
  •  go-up   go-down


69. Sekis I, Gerner W, Willmann M, Rebuzzi L, Tichy A, Patzl M, Thalhammer JG, Saalmüller A, Kleiter MM: Effect of radiation on vascular endothelial growth factor expression in the C2 canine mastocytoma cell line. Am J Vet Res; 2009 Sep;70(9):1141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of radiation on vascular endothelial growth factor expression in the C2 canine mastocytoma cell line.
  • OBJECTIVE: To establish the radiosensitivity and effect of irradiation on vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) expression in the canine mastocytoma cell line C2.
  • SAMPLE POPULATION: Canine mastocytoma cell line C2.
  • PROCEDURES: C2 cells were irradiated with single doses of 2, 4, 6, and 8 Gy.
  • RESULTS: C2 cells secreted VEGF constitutively.
  • Cell survival rates decreased in a dose-dependent manner.
  • The apoptotic cell fraction had a dose-dependent increase that reached its maximum 24 to 48 hours after radiation.
  • CONCLUSIONS AND CLINICAL RELEVANCE: The C2 cell line was radiosensitive, and a fraction (up to 40%) of cells died via apoptosis in a dose-dependent manner.
  • In response to radiation, C2 cells did not upregulate VEGF production or VEGFR.
  • Further studies are needed to determine whether tumor control could be improved by combining radiotherapy with VEGFR inhibitors or apoptosis-modulating agents.
  • [MeSH-major] Dog Diseases / radiotherapy. Mast-Cell Sarcoma / veterinary. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Animals. Annexin A5 / genetics. Apoptosis / radiation effects. Cell Division / radiation effects. Cell Line, Tumor. Dogs. Dose-Response Relationship, Radiation. Humans. Vascular Endothelial Growth Factor Receptor-1 / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719431.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


70. Turrel JM, Farrelly J, Page RL, McEntee MC: Evaluation of strontium 90 irradiation in treatment of cutaneous mast cell tumors in cats: 35 cases (1992-2002). J Am Vet Med Assoc; 2006 Mar 15;228(6):898-901
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of strontium 90 irradiation in treatment of cutaneous mast cell tumors in cats: 35 cases (1992-2002).
  • OBJECTIVE: To determine the efficacy of strontium 90 beta irradiation in the management of cutaneous mast cell tumors (CMCTs) in cats.
  • PROCEDURE: Medical records of cats with CMCTs in which tumors were radiated by use of a strontium 90 ophthalmic applicator from 1992 to 2002 were reviewed.
  • Cats were included if CMCT was diagnosed, there were no other sites of MCT involvement at the time of treatment, and records contained adequate follow-up information to permit retrospective assessment of local tumor control.
  • RESULTS: 54 tumors in 35 cats were treated with a median dose of 135 Gy of strontium 90 beta irradiation, resulting in local tumor control in 53 of 54 (98%) tumors with a median follow-up time of 783 days after treatment.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that strontium 90 beta irradiation resulted in long-term tumor control and should be considered an effective alternative to surgical resection in management of CMCTs in cats.
  • [MeSH-major] Cat Diseases / radiotherapy. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary. Strontium Radioisotopes

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536702.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Strontium Radioisotopes
  •  go-up   go-down


71. Sabattini S, Bettini G: Prognostic value of histologic and immunohistochemical features in feline cutaneous mast cell tumors. Vet Pathol; 2010 Jul;47(4):643-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of histologic and immunohistochemical features in feline cutaneous mast cell tumors.
  • Feline cutaneous mast cell tumors (MCTs) have been histologically classified as mastocytic (well differentiated or pleomorphic) and atypical/poorly granulated.
  • Histologic classification, number of tumors, mitotic index, cytoplasmic granularity, and infiltration by eosinophils or lymphocytes were evaluated retrospectively in 25 feline cutaneous MCTs.
  • The tumors comprised 15 mastocytic well-differentiated, 7 mastocytic pleomorphic, and 3 atypical/poorly granulated MCTs.
  • Immunohistochemically, CD117 was expressed in 13 of 25 tumors (52%), and telomerase reverse transcriptase was expressed in 15 of 22 (68%), with no correlation to histologic classification.
  • Five cats (20%) died of tumor-related causes.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418469.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


72. Shanker A, Buferne M, Schmitt-Verhulst AM: Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology; 2010 Jan;129(1):41-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity.
  • In mice expressing a transgenic T-cell receptor (TCR; TCRP1A) of DBA/2 origin with reactivity towards a cancer-germline antigen P1A, the number of TCRP1A CD8+ T cells in lymphoid organs is lower in DBA/2 than in B10.D2 or B10.D2(x DBA/2)F1 mice.
  • This reduction results from haemopoietic cell autonomous differences in the differentiation of the major histocompatibility complex class I-restricted TCRP1A thymocytes controlled by DBA/2 versus B10.D2-encoded genes.
  • We report here that the lower number of TCRP1A CD8+ T cells in DBA/2 mice correlated with their poor resistance to P1A-expressing mastocytoma solid tumours.
  • Intriguingly, non-transgenic DBA/ 2 mice resisted P1A+ tumours more efficiently despite poor representation of P1A-specific CTL.
  • This was partly the result of their more heterogeneous TCR repertoire, including reactivity to non-P1A tumour antigens because mice that had rejected a P1A+ tumour became resistant to a P1A) variant of the tumour.
  • Nonetheless, reconstitution of RAGo/o mice with TCRP1A CD8+ T cells, with or without CD4+ T cells, or exclusive representation of TCRP1A CD8+ T cells in RAGo/o TCRP1A transgenic mice efficiently resisted the growth of P1A-expressing tumours.
  • Natural killer cells present at a higher number in RAGo/o mice also contributed to tumour resistance, in part through an NKG2D-dependent mechanism.
  • Hence, in the absence of a polyclonal T-cell repertoire, precursor frequencies of natural killer cells and tumour-specific CTL affect tumour resistance.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 1994 May 2;171(1):131-7 [8176234.001]
  • [Cites] Science. 2006 Apr 7;312(5770):114-6 [16513943.001]
  • [Cites] Hybridoma. 1984 Fall;3(3):301-3 [6500587.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):5069-77 [15067090.001]
  • [Cites] J Immunol. 2004 Apr 1;172(7):4215-24 [15034034.001]
  • [Cites] J Immunol. 2003 Dec 15;171(12):6349-54 [14662832.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):361-5 [12640451.001]
  • [Cites] Eur J Immunol. 2003 Feb;33(2):381-91 [12645935.001]
  • [Cites] Annu Rev Immunol. 2003;21:29-70 [12414723.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;975:68-76 [12538155.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4581-9 [12393695.001]
  • [Cites] Immunol Rev. 2002 Oct;188:51-64 [12445281.001]
  • [Cites] Immunol Rev. 2002 Oct;188:22-32 [12445278.001]
  • [Cites] Immunity. 2002 Jul;17(1):19-29 [12150888.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):619-26 [12055624.001]
  • [Cites] Nat Rev Immunol. 2002 Apr;2(4):251-62 [12001996.001]
  • [Cites] Annu Rev Immunol. 2002;20:551-79 [11861612.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1172-80 [11801652.001]
  • [Cites] Adv Immunol. 2001;79:55-92 [11680011.001]
  • [Cites] Nat Immunol. 2001 May;2(5):423-9 [11323696.001]
  • [Cites] Nat Immunol. 2001 May;2(5):415-22 [11323695.001]
  • [Cites] Int Immunol. 2001 May;13(5):625-32 [11312250.001]
  • [Cites] J Immunol. 2000 Dec 15;165(12):6833-9 [11120806.001]
  • [Cites] Immunity. 2000 Aug;13(2):265-76 [10981969.001]
  • [Cites] J Exp Med. 2009 Apr 13;206(4):849-66 [19332877.001]
  • [Cites] J Immunol. 2007 Nov 15;179(10):6651-62 [17982055.001]
  • [Cites] Eur J Immunol. 1994 Nov;24(11):2740-5 [7525302.001]
  • [Cites] Eur J Immunol. 1995 Mar;25(3):664-71 [7705394.001]
  • [Cites] Science. 1996 Apr 5;272(5258):54-60 [8600537.001]
  • [Cites] Eur J Immunol. 1998 Dec;28(12):4010-9 [9862337.001]
  • [Cites] J Exp Med. 1999 Mar 1;189(5):811-20 [10049945.001]
  • [Cites] J Immunol. 1999 Mar 15;162(6):3534-40 [10092811.001]
  • [Cites] Nat Immunol. 2005 Aug;6(8):793-9 [16025119.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):994-9 [16418289.001]
  • [Cites] J Immunol. 2006 Apr 15;176(8):4834-42 [16585578.001]
  • [Cites] J Exp Med. 1991 Jun 1;173(6):1373-84 [1903428.001]
  • (PMID = 20050329.001).
  • [ISSN] 0019-2805
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Receptors, Antigen, T-Cell; 0 / cancer-testis antigen P1A, mouse
  • [Other-IDs] NLM/ PMC2807485
  •  go-up   go-down


73. Akoglu G, Erkin G, Cakir B, Boztepe G, Sahin S, Karaduman A, Atakan N, Akan T, Kolemen F: Cutaneous mastocytosis: demographic aspects and clinical features of 55 patients. J Eur Acad Dermatol Venereol; 2006 Sep;20(8):969-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Mastocytosis is a rare, heterogeneous group of disorder with abnormal increase of mast cells in one or more organ systems.
  • RESULTS: Of the 22 females and 33 males, 80% had urticaria pigmentosa/maculopapular CM and 20% had mastocytoma.
  • CONCLUSION: Clinical presentations of urticaria pigmentosa/maculopapular CM and mastocytoma are similar regarding gender, age of onset, age of diagnosis, and presence of Darier's sign and history of bulla.
  • In contrast to mastocytoma, urticaria pigmentosa/maculopapular CM lesions were frequently located on trunk together with extremities.

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Cutaneous mastocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922947.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


74. Bouabdallah I, M'Barek LA, Zyad A, Ramdani A, Zidane I, Melhaoui A: Anticancer effect of three pyrazole derivatives. Nat Prod Res; 2006 Sep;20(11):1024-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The evaluation of the cytotoxic properties in vitro of three synthetic tripods containing pyrazole: N,N-bis[(3,5-dimethylpyrazol-1-yl)methyl]aniline (1); N,N-tetrakis[(3,5-dimethylpyrazol-1-yl)methyl]-para-phenylenediamine (2); and N,N-tetrakis-[(1,5-dimethylpyrazol-3-yl)methyl]-para-phenylenediamine (3), was examined for their cytotoxic activity on two tumor cell lines: P815 (murin mastocytoma) and Hep (human laryngeal carcinome).
  • While the compound 2 shows a small cytotoxic activity, compounds 1 and 3 are more cytotoxic against both cell lines.
  • However, this cytotoxicity is more pronounced against Hep cell line (IC50: 3.25 microg mL(-1) for compound 1 and 6.92 microg mL(-1) for compound 3) than P815 cell line (IC50: 17.82 microg mL(-1) for compound 1 and 37.21 microg mL(-1) for compound 3).
  • Interestingly, the cytotoxicity induced by compound 1 against Hep cell line is more important than that induced by adriamycin used as a positive control.
  • [MeSH-minor] Cell Line, Tumor. Humans. Molecular Structure

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050185.001).
  • [ISSN] 1478-6419
  • [Journal-full-title] Natural product research
  • [ISO-abbreviation] Nat. Prod. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Antineoplastic Agents; 0 / N,N-bis((3,5-dimethylpyrazol-1-yl)methyl)aniline; 0 / N,N-tetrakis((3,5-dimethylpyrazol-1-yl)methyl)-para-phenylenediamine; 0 / Phenylenediamines; 0 / Pyrazoles
  •  go-up   go-down


75. Avery A: Molecular diagnostics of hematologic malignancies. Top Companion Anim Med; 2009 Aug;24(3):144-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the diagnosis of these diseases can be straightforward, there are many cases in which the diagnosis is difficult to establish with conventional methods.
  • Here, detection of mutations of the c-kit gene in mast cell tumors, the bcr-abl fusion gene in myelogenous leukemias, and clonality of lymphocyte populations for the diagnosis and monitoring of lymphoma and leukemia are discussed.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19732733.001).
  • [ISSN] 1938-9736
  • [Journal-full-title] Topics in companion animal medicine
  • [ISO-abbreviation] Top Companion Anim Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


76. Zhang X, Mei W, Zhang L, Yu H, Zhao X, Fan X, Qian G, Ge S: Co-expression of P1A35-43/beta2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model. Oncol Rep; 2009 Nov;22(5):1213-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-expression of P1A35-43/beta2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model.
  • A strong CTL response is dependent upon a high level of expression of specific class I major histocompatibility complex (MHC)/peptide complexes at the cell surface.
  • In this study, we modified the P1A tumor cell vaccine by addition of the tumor-associated epitope (TAE)-linked beta2m molecule and co-stimulatory molecule CD80 to improve the efficiency in the application of the vaccine.
  • P815 cell lines stably expressing P1A35-43-linked beta2m molecule and/or CD80 were established after transfection, by selection under G418.
  • Administration of these inactivated tumor cell vaccines allowed the TAE-specific CD8+ T cell responses to be examined in vivo.
  • Our results indicate that immunization with P815 cells expressing both the P1A35-43-linked beta2m molecule and the murine CD80 gene elicited a significantly stronger antitumor immune response than the single-modified tumor cell vaccines (expressing either P1A35-43-linked beta2m or CD80 alone).
  • These findings support the feasibility and effectiveness of developing a dual-modified tumor cell vaccine consisting of the epitope-linked beta2m molecule and a co-stimulatory molecule.
  • [MeSH-major] Antigens, CD80 / immunology. Antigens, Neoplasm / immunology. Cancer Vaccines / therapeutic use. Mastocytoma / immunology. Mastocytoma / therapy. beta 2-Microglobulin / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787242.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Recombinant Fusion Proteins; 0 / beta 2-Microglobulin; 0 / tumor rejection antigen P815A, mouse; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


77. Webster JD, Kiupel M, Yuzbasiyan-Gurkan V: Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer; 2006 Apr 01;6:85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.
  • BACKGROUND: Mutations in the c-KIT proto-oncogene have been implicated in the progression of several neoplastic diseases, including gastrointestinal stromal tumors and mastocytosis in humans, and cutaneous mast cell tumors (MCTs) in canines.
  • In contrast, deletions and internal tandem duplication (ITD) mutations are found in the juxtamembrane domain of c-KIT in approximately 15% of canine MCTs.
  • However, some canine MCTs have aberrant KIT localization but lack ITD c-KIT mutations, suggesting that other mutations or other factors may be responsible for aberrant KIT localization in these tumors.
  • METHODS: In order to characterize the prevalence of mutations in the phospho-transferase portion of c-KIT's kinase domain in canine MCTs exons 16-20 of 33 canine MCTs from 33 dogs were amplified and sequenced.
  • CONCLUSION: In conclusion, mutations in the phospho-transferase portion of c-KIT's kinase domain do not play an important role in the progression of canine cutaneous MCTs, or in the aberrant localization of KIT in canine MCTs.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1993 Oct;92(4):1736-44 [7691885.001]
  • [Cites] Neoplasia. 2006 Feb;8(2):104-11 [16611403.001]
  • [Cites] Virchows Arch. 1994;424(2):135-41 [7514077.001]
  • [Cites] J Exp Med. 1994 Jun 1;179(6):1777-87 [7515099.001]
  • [Cites] Biotechniques. 1995 May;18(5):768-70, 772-3 [7619474.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10560-4 [7479840.001]
  • [Cites] Nat Genet. 1996 Mar;12(3):312-4 [8589724.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Hum Pathol. 1998 May;29(5):498-504 [9596274.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2120-9 [9827716.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):53-60 [9916918.001]
  • [Cites] J Invest Dermatol. 1999 Feb;112(2):165-70 [9989791.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1609-14 [9990072.001]
  • [Cites] Exp Hematol. 1999 Apr;27(4):689-97 [10210327.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1643-7 [10362788.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4297-300 [10485475.001]
  • [Cites] J Vet Diagn Invest. 2004 Nov;16(6):554-61 [15586571.001]
  • [Cites] Am J Dermatopathol. 2000 Feb;22(1):49-54 [10698217.001]
  • [Cites] Mamm Genome. 2000 Dec;11(12):1079-86 [11130975.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8118-21 [11719439.001]
  • [Cites] Blood. 2002 Jul 15;100(2):585-93 [12091352.001]
  • [Cites] Vet Pathol. 2002 Sep;39(5):529-35 [12243462.001]
  • [Cites] Am J Vet Res. 2002 Dec;63(12):1718-23 [12492288.001]
  • [Cites] Mol Cell Biol. 2003 May;23(9):3067-78 [12697809.001]
  • [Cites] Cancer Sci. 2003 Jun;94(6):486-91 [12824871.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5729-34 [14654558.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(5):689-95 [15010069.001]
  • [Cites] J Vet Diagn Invest. 2004 Mar;16(2):95-100 [15053358.001]
  • [Cites] Vet Pathol. 2004 Jul;41(4):371-7 [15232137.001]
  • [Cites] Adv Vet Sci Comp Med. 1970;14:309-54 [4922146.001]
  • [Cites] J Natl Cancer Inst. 1973 Feb;50(2):457-66 [4735678.001]
  • [Cites] Aust Vet J. 1979 Dec;55(12):602-4 [231964.001]
  • [Cites] Vet Pathol. 1984 Sep;21(5):469-74 [6435301.001]
  • [Cites] Nature. 1986 Sep 18-24;323(6085):226-32 [3020426.001]
  • [Cites] Aust Vet J. 1987 Jun;64(6):161-4 [3115242.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3341-51 [2448137.001]
  • [Cites] Genes Dev. 1989 Jun;3(6):816-26 [2473008.001]
  • [Cites] Cell. 1990 Oct 5;63(1):195-201 [2208278.001]
  • [Cites] Cell. 1990 Oct 5;63(1):213-24 [1698556.001]
  • [Cites] Cell. 1990 Oct 5;63(1):225-33 [1698557.001]
  • [Cites] EMBO J. 1990 Oct;9(10):3287-94 [1698611.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6382-6 [1712491.001]
  • [Cites] Blood. 1992 Feb 15;79(4):958-63 [1371080.001]
  • [Cites] J Immunol. 1992 Jul 15;149(2):599-608 [1378071.001]
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6139-43 [1384954.001]
  • [Cites] Am J Pathol. 1993 Jan;142(1):339-46 [7678721.001]
  • [Cites] Vet Q. 2004 Dec;26(4):156-69 [15663212.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):634-9 [15917417.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):1042-6 [16143141.001]
  • [Cites] J Immunol. 1994 Jan 1;152(1):213-9 [7504710.001]
  • (PMID = 16579858.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / T32 RR017189; United States / NCRR NIH HHS / RR / T32 RR017189-04; United States / NCRR NIH HHS / RR / T-32 RR17189
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC1448201
  •  go-up   go-down


78. Gamlem H, Nordstoga K, Glattre E: Canine neoplasia--introductory paper. APMIS Suppl; 2008;(125):5-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine neoplasia--introductory paper.
  • The paper gives a brief introduction to canine oncology, including its comparative aspects as basis for recording tumours in the animal kingdom.
  • In an abbreviated presentation of the Norwegian Canine Cancer Project for the years 1990-1998, the data (n=14,401) were divided into age groups, each of two years, into different categories of tumours, and into age and gender.
  • As expected, cutaneous histiocytoma was the dominant tumour type in both sexes during the two first years of life.
  • In the age group 2-3.99 years histiocytoma was still the largest group in males, but was surpassed by benign epithelial skin tumours in females.
  • After the age of 4 years, benign epithelial skin tumours constituted the greatest circumscribed group in males, and mammary tumours in females, although the summated other tumours, not explained in this survey, dominated overall in males.
  • While mastocytoma was the most common tumour and non-Hodgkin's lymphoma the second most common during the two first years of life in females, the situation was reversed in males.
  • Later, mammary tumours dominated in females, while different tumour types not further specified in this summarized report dominated in males, until the end of the age registration (above 14 years).
  • Number, sex and location of most common tumours are shown in a tabular outline.
  • Comparative aspects between human and dog tumours are considered: mammary and testicular neoplasia seemed more frequent in dogs than in humans in Norway, while intestinal, pulmonary and prostatic malignancies were less common in dogs.
  • In our study, vascular tumours and tumour-like lesions constituted about 3% of the total data.
  • As benign vascular tumours are incompletely reported to the human Cancer Registry, no dependable comparison may be made, but malignant vascular tumours have been on the rise during the last decades in the Norwegian human population, more so in men then in women.
  • Finally, the article deals briefly with the development of endothelial cells, and the sparse information on causal factors of vascular tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385278.001).
  • [ISSN] 0903-465X
  • [Journal-full-title] APMIS. Supplementum
  • [ISO-abbreviation] APMIS Suppl.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 55
  •  go-up   go-down


79. Bağriaçik EÜ, Uslu K, Yurtçu E, Stefek M, Karasu C: Stobadine inhibits doxorubicin-induced apoptosis through a caspase-9 dependent pathway in P815 mastocytoma cells. Cell Biol Int; 2007 Sep;31(9):979-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stobadine inhibits doxorubicin-induced apoptosis through a caspase-9 dependent pathway in P815 mastocytoma cells.
  • Doxorubicin (DOXO), a widely used chemotherapeutic agent, induces apoptosis in transformed and non-transformed cells.
  • In the present study we investigated the effects of stobadine, a pyridoindole antioxidant in a DOXO-induced apoptosis model of P815 cells by flow cytometric analyses and by measuring caspase-3 and caspase-9 activities.
  • Pretreating cells with stobadine significantly increased cell viability and decreased apoptosis rate.
  • Inhibition in apoptosis was observed at maximum levels following treatment of cells with 10(-7)M stobadine as evident from flow cytometric analyses.
  • We found that the antioxidative effects of stobadine were comparable to the effects of a well known antioxidant, N-acetyl l-cysteine (NAC).
  • [MeSH-major] Apoptosis / drug effects. Carbolines / pharmacology. Caspase 9 / metabolism. Doxorubicin / pharmacology. Mastocytoma / enzymology. Mastocytoma / pathology

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481927.001).
  • [ISSN] 1065-6995
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Carbolines; 0 / Caspase Inhibitors; 80168379AG / Doxorubicin; EC 3.4.22.- / Caspase 9; WYQ7N0BPYC / Acetylcysteine; Y0EA50IJ3V / dicarbine
  •  go-up   go-down


80. Uehlinger FD, Burton SA, Riley CB, Wichtel ME, Bourque AC: Cutaneous and tendon sheath mastocytomas with eosinophilic joint and tendon sheath effusions in a horse. J Vet Intern Med; 2010 Sep-Oct;24(5):1233-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous and tendon sheath mastocytomas with eosinophilic joint and tendon sheath effusions in a horse.

  • MedlinePlus Health Information. consumer health - Joint Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. Phenylbutazone .
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20707847.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics; 0 / Anti-Inflammatory Agents, Non-Steroidal; 76I7G6D29C / Morphine; 7S5I7G3JQL / Dexamethasone; GN5P7K3T8S / Phenylbutazone; QV897JC36D / Butorphanol
  •  go-up   go-down


81. Gaje P, Bocan V, Cîmpean AM, Izvernariu DA, Streian F, Raica M: Simultaneous demonstration of mast cells and blood vessels by the combined method CD34--alcian blue-safranin in lip tumors. Rom J Morphol Embryol; 2007;48(3):237-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous demonstration of mast cells and blood vessels by the combined method CD34--alcian blue-safranin in lip tumors.
  • The aim of the study was to evaluate the mast cell-blood vessel relationship using double staining CD34/AAS.
  • Sections from 14 cases with lip tumors have been stained with Hematoxylin-Eosin.
  • On additional sections from each case, we highlighted blood vessels by immunohistochemistry for CD34 antigen using the method LSAB2-HRP/DAB, followed by alcian blue-safranin stain for mast cells.
  • We quantified the density, distribution and the mast cell types as well as the correlation with the number of blood vessels.
  • We observed a significant correlation between the number of vessels and the mast cells (p = 0.003).
  • In one case, we observed the mast cells stained with safranin (red), the vascular density being less than the mast cells density.
  • Our results confirmed the data from the literature with respect to the large number of mast cells observed in the malignant tumors.
  • The increased vascular density together with the mast cell density suggests a correlation between these two elements in the tumor angiogenesis, possibly though the VEGF secretion.
  • The CD34/AAS stain is a quick and simple method and it allows an optimal correlation between the number of mast cells and blood vessels on the same section.
  • The type of mast cells correlated with microvessel density is a powerful argument towards the involvement of the mast cells in the tumor angiogenesis of the malignances of the lips.
  • [MeSH-major] Alcian Blue. Antigens, CD34 / metabolism. Blood Vessels / metabolism. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lip Neoplasms / diagnosis. Mast Cells / metabolism. Phenazines
  • [MeSH-minor] Humans. Neovascularization, Pathologic / diagnosis

  • Hazardous Substances Data Bank. C.I. BASIC RED 2 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914489.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Phenazines; P4448TJR7J / Alcian Blue; XTX0YXU2HV / safranine T
  •  go-up   go-down


82. Conti P, Castellani ML, Kempuraj D, Salini V, Vecchiet J, Tetè S, Mastrangelo F, Perrella A, De Lutiis MA, Tagen M, Theoharides TC: Role of mast cells in tumor growth. Ann Clin Lab Sci; 2007;37(4):315-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of mast cells in tumor growth.
  • The growth of malignant tumors is determined in large part by the proliferative capacity of the tumor cells.
  • Clinical observations and animal experiments have established that tumor cells elicit immune responses.
  • Histopathologic studies show that many tumors are surrounded by mononuclear cell and mast cell infiltrates.
  • Mast cells are ubiquitous in the body and are critical for allergic reactions.
  • Increasing evidence indicates that mast cells secrete proinflammatory cytokines and are involved in neuro-inflammatory processes and cancer.
  • Mast cells accumulate in the stroma surrounding certain tumors, especially mammary adenocarcinoma, and the molecules they secrete can benefit the tumor.
  • However, mast cells can also increase at the site of tumor growth and participate in tumor rejection.
  • Mast cells may be recruited by tumor-derived chemoattractants and selectively secrete molecules such as growth factors, histamine, heparin, VEGF, and IL-8, as well as proteases that permit the formation of new blood vessels and metastases.
  • Tumor mast cell intersections play regulatory and modulatory roles affecting various aspects of tumor growth.
  • Discovery of these new roles of mast cells further complicates the understanding of tumor growth.
  • This review focuses on the strategic importance of mast cells to the progression of tumors, and proposes a revised immune effector mechanism of mast cell involvement in tumor growth.
  • [MeSH-major] Mast Cells / immunology. Neoplasms / physiopathology
  • [MeSH-minor] Cell Proliferation. Cytokines / metabolism. Cytokines / secretion. Histamine / metabolism. Humans. Neovascularization, Pathologic / immunology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HISTAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18000287.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 820484N8I3 / Histamine
  • [Number-of-references] 50
  •  go-up   go-down


83. Payne RJ, Lean MS, Greet TR: Third eyelid resection as a treatment for suspected squamous cell carcinoma in 24 horses. Vet Rec; 2009 Dec 26;165(25):740-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Third eyelid resection as a treatment for suspected squamous cell carcinoma in 24 horses.
  • Between October 2000 and January 2007, 24 horses were presented with suspected squamous cell carcinoma (SCC) of the third eyelid.
  • SCC was confirmed in 16 of these 21 cases, three cases were diagnosed histologically as lymphoid hyperplasia, one as a mast cell tumour and one as a sebaceous gland adenocarcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Eyelid Neoplasms / veterinary. Horse Diseases / surgery. Nictitating Membrane
  • [MeSH-minor] Animals. Female. Horses. Male. Neoplasm Recurrence, Local / veterinary. Retrospective Studies. Treatment Outcome

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023277.001).
  • [ISSN] 2042-7670
  • [Journal-full-title] The Veterinary record
  • [ISO-abbreviation] Vet. Rec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Miyajima N, Watanabe M, Ohashi E, Mochizuki M, Nishimura R, Ogawa H, Sugano S, Sasaki N: Relationship between retinoic acid receptor alpha gene expression and growth-inhibitory effect of all-trans retinoic acid on canine tumor cells. J Vet Intern Med; 2006 Mar-Apr;20(2):348-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between retinoic acid receptor alpha gene expression and growth-inhibitory effect of all-trans retinoic acid on canine tumor cells.
  • Retinoids show antitumor effects on human acute promyelocytic leukemia and other tumors via retinoid receptors.
  • In dogs, the role of retinoid receptors in inhibiting tumor development remains unclear.
  • To evaluate the correlation between the degree of expression of retinoic acid receptor alpha (RARalpha) mRNA and the antiproliferative effects of all-trans retinoic acid (ATRA) treatments, expression analysis of RARalpha mRNA and cell growth inhibition assay were performed on 17 established canine tumor cell lines, including 6 mammary gland tumor (MGT) cell lines, 3 osteosarcoma cell lines, 5 melanoma cell lines, and 3 mast cell tumor (MCT) cell lines.
  • Among the cell lines investigated, all 3 MCT cell lines showed high expression of RARalpha, and the most effective cell growth inhibition was observed in ATRA-treated MCT cell lines.
  • However, remarkable antiproliferative effects of ATRA treatments were not observed on other tumor cell lines with moderate or low RARalpha mRNA expression.
  • Furthermore, real-time quantitative polymerase chain reaction analysis of RARalpha was performed on MCT tissue samples of dogs with spontaneous disease, and 5 of 9 tissues showed high expression.

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16594593.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 5688UTC01R / Tretinoin
  •  go-up   go-down


85. Kim MS, Kuehn HS, Metcalfe DD, Gilfillan AM: Activation and function of the mTORC1 pathway in mast cells. J Immunol; 2008 Apr 1;180(7):4586-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation and function of the mTORC1 pathway in mast cells.
  • Little is known about the signals downstream of PI3K which regulate mast cell homeostasis and function following FcepsilonRI aggregation and Kit ligation.
  • In human and mouse mast cells, stimulation via FcepsilonRI or Kit resulted in a marked PI3K-dependent activation of the mTORC1 pathway, as revealed by the wortmannin-sensitive sequential phosphorylation of tuberin, mTOR, p70S6 kinase (p70S6K), and 4E-BP1.
  • In contrast, in human tumor mast cells, the mTORC1 pathway was constitutively activated and this was associated with markedly elevated levels of mTORC1 pathway components.
  • In parallel, although rapamycin had no effect on FcepsilonRI-mediated degranulation or Kit-mediated cell adhesion, it inhibited cytokine production, and kit-mediated chemotaxis and cell survival.
  • Furthermore, Rapamycin also blocked the constitutive activation of the mTORC1 pathway and inhibited cell survival of tumor mast cells.
  • These data provide evidence that mTORC1 is a point of divergency for the PI3K-regulated downstream events of FcepsilonRI and Kit for the selective regulation of mast cell functions.
  • Specifically, the mTORC1 pathway may play a critical role in normal and dysregulated control of mast cell homeostasis.
  • [MeSH-major] Mast Cells / immunology. Mast Cells / metabolism. Signal Transduction / immunology. Transcription Factors / immunology. Transcription Factors / metabolism
  • [MeSH-minor] Animals. Cell Survival. Cells, Cultured. Humans. Kinetics. Mice. Multiprotein Complexes. Neoplasms / metabolism. Neoplasms / pathology. Phosphatidylinositol 3-Kinases / metabolism. Proteins. Proto-Oncogene Proteins c-kit / metabolism. Receptors, IgE / immunology. Sirolimus / pharmacology. TOR Serine-Threonine Kinases

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1053-74 [10582339.001]
  • [Cites] Novartis Found Symp. 2005;271:152-61; discussion 161-5, 198-9 [16605133.001]
  • [Cites] Nature. 2001 Jul 12;412(6843):186-90 [11449275.001]
  • [Cites] Immunity. 2002 Mar;16(3):441-51 [11911828.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4871-80 [11994436.001]
  • [Cites] Cell. 2002 Jul 26;110(2):163-75 [12150925.001]
  • [Cites] Cell. 2002 Jul 26;110(2):177-89 [12150926.001]
  • [Cites] J Immunol Methods. 2002 Oct 15;268(2):239-43 [12215392.001]
  • [Cites] Nat Rev Immunol. 2002 Oct;2(10):773-86 [12360215.001]
  • [Cites] Nature. 2006 May 25;441(7092):424-30 [16724053.001]
  • [Cites] J Allergy Clin Immunol. 2006 Jun;117(6):1214-25; quiz 1226 [16750977.001]
  • [Cites] Immunol Res. 2006;34(2):97-115 [16760571.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1065-72 [16597595.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):671-88 [16883305.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2366-72 [16741248.001]
  • [Cites] Oncogene. 2006 Oct 16;25(48):6373-83 [17041623.001]
  • [Cites] Dev Cell. 2006 Dec;11(6):859-71 [17141160.001]
  • [Cites] J Exp Med. 2007 Jan 22;204(1):93-103 [17190838.001]
  • [Cites] Nat Rev Immunol. 2007 Feb;7(2):93-104 [17259966.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4177-83 [17371974.001]
  • [Cites] Trends Immunol. 2007 May;28(5):234-41 [17400512.001]
  • [Cites] Leuk Res. 2003 Aug;27(8):677-82 [12801524.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4412-9 [12907613.001]
  • [Cites] J Mol Med (Berl). 2003 Sep;81(9):524-35 [12928787.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):48474-84 [13129935.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7254-62 [15187100.001]
  • [Cites] Blood. 2004 Jul 1;104(1):207-14 [15010370.001]
  • [Cites] Arerugi. 2004 Jun;53(6):557-61 [15247516.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(15):6710-8 [15254238.001]
  • [Cites] Curr Biol. 2004 Jul 27;14(14):1296-302 [15268862.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2410-7 [15217825.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9508-16 [15485918.001]
  • [Cites] Nature. 2004 Oct 21;431(7011):1007-11 [15496927.001]
  • [Cites] J Immunol Methods. 1986 May 22;89(2):271-7 [3486233.001]
  • [Cites] J Immunol. 1992 Feb 1;148(3):772-7 [1370517.001]
  • [Cites] J Exp Med. 1992 Jan 1;175(1):237-44 [1370529.001]
  • [Cites] Eur J Immunol. 1993 Dec;23(12):3286-91 [7504992.001]
  • [Cites] Scand J Immunol. 1994 May;39(5):489-98 [8191224.001]
  • [Cites] J Immunol. 1994 Oct 15;153(8):3717-23 [7523504.001]
  • [Cites] J Immunol. 1996 Mar 1;156(5):1942-5 [8596048.001]
  • [Cites] Mol Biol Cell. 1997 May;8(5):909-22 [9168474.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2333-42 [10498605.001]
  • [Cites] Trends Mol Med. 2005 Aug;11(8):353-61 [16002336.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Nat Rev Immunol. 2006 Mar;6(3):218-30 [16470226.001]
  • [Cites] FASEB J. 2006 Mar;20(3):455-65 [16507763.001]
  • [Cites] J Exp Med. 2000 Sep 4;192(5):729-40 [10974038.001]
  • (PMID = 18354181.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AI000965-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multiprotein Complexes; 0 / Proteins; 0 / Receptors, IgE; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS112335; NLM/ PMC2698706
  •  go-up   go-down


86. Fujimi K, Uehara Y, Abe S, Kawamura A, Devarajan S, Miura S, Saku K, Urata H: Homocysteine-induced oxidative stress upregulates chymase in mouse mastocytoma cells. Hypertens Res; 2010 Feb;33(2):149-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homocysteine-induced oxidative stress upregulates chymase in mouse mastocytoma cells.
  • In this study, we tested whether oxidative stress upregulates mouse mast cell proteinase chymase, mouse mast cell proteinase (MMCP)-5 or MMCP-4.
  • Cultured mouse mastocytoma cells (MMC) displaying chymase-dependent Ang II-forming activity were treated with H(2)O(2) and several aminothiols with or without anti-oxidants.
  • Homocysteine increased mast cell chymase expression and activity through the mechanism of oxidative stress.
  • [MeSH-major] Chymases / genetics. Homocysteine / pharmacology. Mastocytoma / enzymology. Oxidative Stress
  • [MeSH-minor] Angiotensin II / biosynthesis. Animals. Cell Line, Tumor. Mice. RNA, Messenger / analysis. Reactive Oxygen Species / metabolism. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19960020.001).
  • [ISSN] 1348-4214
  • [Journal-full-title] Hypertension research : official journal of the Japanese Society of Hypertension
  • [ISO-abbreviation] Hypertens. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 0LVT1QZ0BA / Homocysteine; 11128-99-7 / Angiotensin II; EC 3.4.21.39 / Chymases
  •  go-up   go-down


87. Wright ZM, Chretin JD: Diagnosis and treatment of a feline oral mast cell tumor. J Feline Med Surg; 2006 Aug;8(4):285-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of a feline oral mast cell tumor.
  • A cat was diagnosed with an oral mast cell tumor following incisional biopsy.
  • The location of the tumor, possible metastasis, financial restraint and patient disposition severely limited therapeutic options.
  • This is the first documented case of feline oral mast cell tumor and one of a small group of cats with various cancers to be responsive to CCNU treatment.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Cat Diseases / diagnosis. Cat Diseases / drug therapy. Lomustine / administration & dosage. Mast-Cell Sarcoma / veterinary. Mouth Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616568.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


88. Roskoski R Jr: Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. Biochem Biophys Res Commun; 2005 Dec 23;338(3):1307-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
  • Signaling by stem cell factor and Kit, its receptor, play important roles in gametogenesis, hematopoiesis, mast cell development and function, and melanogenesis.
  • Moreover, human and mouse embryonic stem cells express Kit transcripts.
  • Stem cell factor exists as both a soluble and a membrane-bound glycoprotein while Kit is a glycoprotein receptor protein-tyrosine kinase.
  • The complete absence of stem cell factor or Kit is lethal.
  • Gain-of-function mutations of Kit are associated with several human neoplasms including acute myelogenous leukemia, gastrointestinal stromal tumors, mastocytomas, and nasal T-cell lymphomas.
  • Binding of stem cell factor to Kit results in receptor dimerization and activation of protein kinase activity.
  • The majority of human gastrointestinal stromal tumors have Kit gain-of-function mutations in the juxtamembrane domain, and most people with these tumors respond to STI-571.


89. Nomi H, Tashiro-Yamaji J, Yamamoto Y, Miura-Takeda S, Miyoshi-Higashino M, Takahashi T, Azuma H, Ueda H, Katsuoka Y, Kubota T, Yoshida R: Acute rejection of allografted CTL-susceptible leukemia cells from perforin/Fas ligand double-deficient mice. J Immunol; 2007 Aug 15;179(4):2180-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute rejection of allografted CTL-susceptible leukemia cells from perforin/Fas ligand double-deficient mice.
  • The generation of knockout mice demonstrated that CD4(+), but not CD8(+), T cells were essential for the rejection of allografted skin or heart, presumably because these targets were CTL resistant.
  • In the case of CTL-susceptible targets (e.g., P815 mastocytoma cells and EL-4 or RLmale1 T lymphoma cells), however, it is assumed that the CTL is the effector cell responsible for allograft rejection and that perforin and Fas ligand (FasL) pathways are the killing mechanisms.
  • In the present study, we examined the role of these cytotoxic molecules in the rejection of i.p. allografted CTL-susceptible leukemia cells.
  • Unexpectedly, the allografted leukemia cells were acutely rejected from gld (a mutation of FasL), perforin(-/-), or double-deficient mice.
  • The peritoneal exudate cells from gld or normal mice showed T cell-, TCRalphabeta-, and perforin-dependent cytotoxic activity against the allograft, whereas the exudate cells from perforin(-/-) mice exhibited almost full cytotoxic activity in the presence of Fas-Fc.
  • Furthermore, the infiltrates from double-deficient mice showed a high cytotoxic activity against the allografted cells even in the presence of anti-TCRalphabeta Ab or in the absence of T cells.
  • The cytotoxic cells appeared to be macrophages, because they were Mac-1(+) mononuclear cells with a kidney- or horseshoe-shaped nucleus and because the cytotoxic activity was completely suppressed by the addition of N(G)-monomethyl-l-arginine, an inhibitor of inducible NO synthase.
  • [MeSH-minor] Animals. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Line, Tumor. Cell Nucleus / immunology. Enzyme Inhibitors / pharmacology. Leukemia / genetics. Leukemia / immunology. Macrophage-1 Antigen / genetics. Macrophage-1 Antigen / immunology. Mice. Mice, Inbred BALB C. Mice, Knockout. Neoplasm Transplantation / immunology. Nitric Oxide Synthase Type II / antagonists & inhibitors. Nitric Oxide Synthase Type II / immunology. Perforin. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, alpha-beta / immunology. Transplantation, Homologous. omega-N-Methylarginine / pharmacology

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675477.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Fas Ligand Protein; 0 / Macrophage-1 Antigen; 0 / Membrane Glycoproteins; 0 / Pore Forming Cytotoxic Proteins; 0 / Receptors, Antigen, T-Cell, alpha-beta; 126465-35-8 / Perforin; 27JT06E6GR / omega-N-Methylarginine; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nos2 protein, mouse
  •  go-up   go-down


90. Seeliger F, Hess O, Pröpsting MJ, Naim HY, Kleinschmidt S, Woehrmann T, Germann PG, Baumgärtner W: Confocal laser scanning analysis of an equine oral mast cell tumor with atypical expression of tyrosine kinase receptor C-KIT. Vet Pathol; 2007 Mar;44(2):225-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal laser scanning analysis of an equine oral mast cell tumor with atypical expression of tyrosine kinase receptor C-KIT.
  • A 20-year-old female horse showed a nodular, firm, focal ulcerated mast cell tumor at the right dorsobuccal face of the tongue.
  • Histologically, the nonencapsulated tumor consisted of dense, infiltrating aggregates of well-differentiated, Cresyl violet-positive mast cells accompanied by numerous eosinophils.
  • Confocal laser scanning microscopy confirmed an aberrant spatial colocalization of KIT in the Golgi apparatus, which may be the result of a defective protein processing within the tumor cells.
  • The tumor was not associated with a poor prognosis.
  • [MeSH-major] Horse Diseases / enzymology. Horse Diseases / pathology. Mastocytoma / veterinary. Proto-Oncogene Proteins c-kit / biosynthesis. Tongue Neoplasms / enzymology. Tongue Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Vet Pathol. 2007 May;44(3):427. Pröbsting, M [corrected to Pröpsting, M J]; Naim, H Y [added]
  • (PMID = 17317803.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


91. Hosoya K, Kisseberth WC, Alvarez FJ, Lara-Garcia A, Beamer G, Stromberg PC, Couto CG: Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors. J Am Anim Hosp Assoc; 2009 Jan-Feb;45(1):14-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors.
  • The use of adjuvant 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; lomustine) to treat incompletely excised canine mast cell tumors (MCTs) has not been evaluated.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Dog Diseases / drug therapy. Lomustine / therapeutic use. Mast-Cell Sarcoma / veterinary. Prednisone / therapeutic use

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122059.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 7BRF0Z81KG / Lomustine; VB0R961HZT / Prednisone
  •  go-up   go-down


92. Alsharqi A, Parslew R, Shukla R: A 3-month-old with a blistering plaque. Dermatol Online J; 2010;16(9):10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of a 3-month-old child with a solitary mastocytoma who was initially diagnosed with recurrent bullous impetigo.
  • Solitary mastocytoma can present as a blister.
  • Although bullous impetigo is a common diagnosis in children and it would be tempting to make that diagnosis in the presence of a positive skin swab culture, clinicians always have to be mindful of secondary impetiginization of another primary skin disease process.
  • [MeSH-major] Mastocytoma, Skin / diagnosis
  • [MeSH-minor] Blister / etiology. Diagnosis, Differential. Erythema / etiology. Female. Humans. Impetigo / etiology. Infant. Leg / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20875331.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Lachowicz JL, Post GS, Brodsky E: A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats. J Vet Intern Med; 2005 Nov-Dec;19(6):860-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats.
  • A phase I clinical trial evaluating the toxicity of orally-administered imatinib mesylate was performed in 9 tumor-bearing cats.
  • Cats included in the study had diagnoses of fibrosarcoma, squamous cell carcinoma, and mast cell tumor, and each cat was staged using CBC and serum biochemistry; urinalysis, thoracic radiographs, and abdominal ultrasonography were performed in some cats.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16355681.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


94. Krishnan KR, Ownby DR: A solitary mastocytoma presenting with urticaria and angioedema in a 14-year-old boy. Allergy Asthma Proc; 2010 Nov-Dec;31(6):520-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A solitary mastocytoma presenting with urticaria and angioedema in a 14-year-old boy.
  • The differential diagnosis for urticaria is broad, making the evaluation and pinpointing the underlying cause difficult and frustrating for both families and physicians.
  • Mastocytosis is a rare disease that very seldom presents with urticaria but may be associated with significant morbidity and mortality if not recognized in a timely manner.
  • We are presenting a case of a 14-year-old boy who presented with urticaria and angioedema possibly caused by a solitary mastocytoma.
  • The learning points from this case are that mastocytosis should be considered in the differential diagnosis of urticaria and solitary mastocytomas may remain active into adolescence, raising concern for systemic progression.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21708063.001).
  • [ISSN] 1539-6304
  • [Journal-full-title] Allergy and asthma proceedings
  • [ISO-abbreviation] Allergy Asthma Proc
  • [Language] ENG
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


95. Takahashi T, Ohashi E, Nakagawa T, Mochizuki M, Nishimura R, Sasaki N: Role of beta1 integrins in adhesion of canine mastocytoma cells to extracellular matrix proteins. J Vet Med Sci; 2007 May;69(5):495-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of beta1 integrins in adhesion of canine mastocytoma cells to extracellular matrix proteins.
  • The interactions of tumor cells with the extracellular matrix (ECM) are a crucial step in invasion and metastasis.
  • In this study, mastocytoma (mast cell tumor: MCT) cell-ECM interaction was investigated using 3 canine MCT cell lines: CM-MC (originating from cutaneous MCT), VI-MC (originating from intestinal MCT), and CoMS (originating from oral MCT).
  • Flow cytometric analysis showed that all cells highly expressed the integrin beta1 and alpha1 through alpha5 subunits and that they moderately expressed the alpha6 subunit.
  • In adhesion studies, CoMS weakly but spontaneously adhered to fibronectin (FN), which was enhanced by phorbol ester (TPA), while CM-MC and VI-MC required cell activation by TPA to adhere to FN.
  • Anti-beta1 and alpha5 integrin antibodies strongly inhibited cell adhesion to FN in CM-MC and CoMS and moderately inhibited cell adhesion in VI-MC.
  • Anti-beta1 integrin antibodies strongly inhibited cell adhesion to LN, but all anti-alpha integrin antibodies failed to inhibit cell adhesion to LN.
  • No cells adhered to collagen types I and IV.
  • Canine MCT cells from different origins expressed similar integrin patterns; however, there were some differences in adhesive behavior in response to various ECM proteins and activating stimuli.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551222.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Extracellular Matrix Proteins; 0 / Integrin beta Chains
  •  go-up   go-down


96. O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ: The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol; 2010 Dec;5(12):2024-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of inflammation in the pathogenesis of non-small cell lung cancer.
  • Compelling evidence has accumulated that histologic assessment of infiltration patterns of different host immune response components in non-small cell lung cancer specimens helps identify different prognostic patient subgroups.
  • The usefulness of quantification of different populations of lymphocytes, natural killer cells, macrophages, and mast cells within the tumor microenvironment in non-small cell lung cancer is also discussed.
  • In particular, the importance of assessment of inflammatory cell microlocalization within both the tumor islet and surrounding stromal components is emphasized.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / etiology. Inflammation / complications. Lung Neoplasms / etiology
  • [MeSH-minor] Adaptive Immunity. Animals. CD4-Positive T-Lymphocytes / immunology. Chronic Disease. Humans. Immunity, Cellular. Occupational Exposure / adverse effects. Prognosis. Pulmonary Disease, Chronic Obstructive / complications. Tobacco Smoke Pollution / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21155185.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tobacco Smoke Pollution
  •  go-up   go-down


97. Satake A, Inoue T, Kubo S, Taniguchi Y, Imado T, Fujioka T, Horiuchi M, Xu Y, Ikegame K, Yoshihara S, Kaida K, Tamaki H, Okada M, Okamura H, Ogawa H: Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells. Int J Hematol; 2010 Apr;91(3):485-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with both graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects.
  • Recipient BDF1 (H-2(b/d)) mice received T cell-depleted bone marrow and spleen cells from B6C3F1 (H-2(b/k)) or C57BL/6 (H-2(b)) mice with or without P815 mastocytoma cells (H-2(d)) after receiving lethal total body irradiation.
  • Compared with C57BL/6 --> BDF1 recipients, significantly higher in vitro cytotoxic activity against P815 cells was observed in B6C3F1 --> BDF1 recipients.
  • Significantly lower CXCR3 expression on donor T cells and higher interferon (IFN)-gamma expression were considered to be associated with strong antileukemic effects with less severe GVHD in B6C3F1 --> BDF1 recipients.
  • Furthermore, host immune cells, especially natural killer cells and CD8(+) T cells, were found to contribute remarkably to high IFN-gamma production in B6C3F1 --> BDF1 recipients.
  • Thus, in MHC-haploidentical HSCT, host immune cells may change the balance between GVH and GVL response through IFN-gamma production.
  • [MeSH-major] Bone Marrow Transplantation / immunology. Graft vs Host Disease / immunology. Graft vs Host Disease / pathology. Graft vs Leukemia Effect / immunology. Major Histocompatibility Complex / immunology
  • [MeSH-minor] Animals. CD8-Positive T-Lymphocytes / cytology. CD8-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / metabolism. Cells, Cultured. Female. Flow Cytometry. Haplotypes. Histocompatibility / immunology. Interferon-gamma / immunology. Interferon-gamma / metabolism. Intestine, Large / immunology. Intestine, Large / pathology. Killer Cells, Natural / cytology. Killer Cells, Natural / immunology. Killer Cells, Natural / metabolism. Liver / immunology. Liver / pathology. Lymphocyte Culture Test, Mixed. Mice. Mice, Inbred C3H. Mice, Inbred C57BL. Mice, Inbred DBA. Receptors, CXCR3 / immunology. Receptors, CXCR3 / metabolism. Spleen / cytology

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunol Lett. 2007 Jun 15;110(2):91-100 [17507101.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):910-9 [15240678.001]
  • [Cites] Transplantation. 1986 Sep;42(3):229-34 [3529523.001]
  • [Cites] Biol Blood Marrow Transplant. 1999;5(3):133-43 [10392959.001]
  • [Cites] Blood. 2000 May 1;95(9):2754-9 [10779417.001]
  • [Cites] J Immunol. 1986 Nov 15;137(10):3100-8 [2945856.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(6):604-12 [11128810.001]
  • [Cites] J Immunol. 1993 Dec 1;151(11):6451-9 [8245478.001]
  • [Cites] Transplantation. 1985 Jul;40(1):39-44 [3892795.001]
  • [Cites] J Clin Oncol. 1983 Sep;1(9):517-31 [6366143.001]
  • [Cites] Int Immunol. 1998 Nov;10(11):1593-8 [9846688.001]
  • [Cites] Bone Marrow Transplant. 2003 Mar;31(6):507-10 [12665848.001]
  • [Cites] Eur J Immunol. 2008 Jun;38(6):1745-55 [18493986.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1114-23 [17761834.001]
  • [Cites] Blood. 2009 Apr 9;113(15):3612-9 [19211507.001]
  • [Cites] Cancer Res. 1990 Sep 1;50(17):5414-20 [2117482.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):897-908 [9670968.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 23;103(21):8036-41 [16698926.001]
  • [Cites] J Exp Med. 2005 Jun 20;201(12):1925-35 [15967822.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1073-84 [17084371.001]
  • [Cites] Nat Immunol. 2002 Jun;3(6):549-57 [12006974.001]
  • [Cites] Exp Hematol. 2008 Jan;36(1):1-8 [17920757.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1123-32 [16200070.001]
  • [Cites] J Immunol. 1998 Oct 15;161(8):3957-65 [9780164.001]
  • [Cites] Blood. 2007 Aug 1;110(3):1064-72 [17449800.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Apr;11(4):280-7 [15812393.001]
  • [Cites] Immunol Rev. 1985 Dec;88:193-214 [3910557.001]
  • [Cites] Stem Cells. 2009 Sep;27(9):2185-95 [19557831.001]
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e26 [18232731.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):957-64 [12461568.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6639-48 [17982120.001]
  • [Cites] Transplantation. 2004 Aug 15;78(3):488-9 [15316386.001]
  • [Cites] Science. 2000 Nov 17;290(5495):1354-8 [11082062.001]
  • [Cites] Nat Immunol. 2003 Feb;4(2):154-60 [12524535.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3230-9 [8963063.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1260-5 [15531883.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4207-15 [12010827.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):2-8 [16399577.001]
  • (PMID = 20300982.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cxcr3 protein, mouse; 0 / Receptors, CXCR3; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


98. Tran DT, Jokinen CH, Argenyi ZB: Histiocyte-rich pleomorphic mastocytoma: an uncommon variant mimicking juvenile xanthogranuloma and Langerhans cell histiocytosis. J Cutan Pathol; 2009 Nov;36(11):1215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histiocyte-rich pleomorphic mastocytoma: an uncommon variant mimicking juvenile xanthogranuloma and Langerhans cell histiocytosis.
  • A biopsy demonstrated a large intradermal nodule composed of unusually large epithelioid mast cells, including a prominent subset with bi-lobed and multi-lobed nuclei.
  • By immunohistochemistry, the cells expressed CD117 (C-Kit), mast cell tryptase, CD68, and CD25, and were negative for CD163, CD1a, and S-100, confirming the diagnosis of mastocytoma.
  • Equally prominent was an admixed infiltrate of CD68 and CD163-positive xanthomatous histiocytes that included Touton-type giant cells.
  • However, given the unusual cytologic features, close clinical observation is warranted, as the long-term biologic potential of mastocytoma with this degree of cytologic atypia is uncertain.
  • Awareness of this unusual morphologic variant is also important as the histologic features may mimic such childhood neoplasms as juvenile xanthogranuloma and Langerhans cell histiocytosis.
  • [MeSH-major] Histiocytes / pathology. Mastocytoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Histiocytosis, Langerhans-Cell / pathology. Humans. Immunohistochemistry. Neck / pathology. Xanthogranuloma, Juvenile / pathology


99. Bailey DB, Rassnick KM, Kristal O, Chretin JD, Balkman CE: Phase I dose escalation of single-agent vinblastine in dogs. J Vet Intern Med; 2008 Nov-Dec;22(6):1397-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ANIMALS: Twenty-three dogs with lymphoma or cutaneous mast cell tumors.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19000250.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


100. Fröberg GK, Lindberg R, Ritter M, Nordlind K: Expression of serotonin and its 5-HT1A receptor in canine cutaneous mast cell tumours. J Comp Pathol; 2009 Aug-Oct;141(2-3):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of serotonin and its 5-HT1A receptor in canine cutaneous mast cell tumours.
  • Mast cells of a number of different animal species have been reported to contain serotonin (5-hydroxytryptamine; 5-HT), a monoamine capable of numerous and complex actions, which may include an impact on tumour growth.
  • Limited previous studies have suggested that normal or neoplastic canine mast cells do not express 5-HT.
  • In the present study, canine cutaneous mast cell tumours (MCTs) of Patnaik histological grades I-III were investigated immunohistochemically for expression of 5-HT and its receptor (R) 5-HT1A.
  • The proportion of positively labelled cells and the intensity of labelling of individual cells were determined.
  • Both 5-HT and the 5-HT1A receptor were expressed by non-neoplastic dermal mast cells and neoplastic mast cells.
  • More neoplastic mast cells expressed 5-HT than the 5-HT1AR.
  • Poorly differentiated tumours expressed fewer of both molecules, but the better differentiated mast cells at the periphery of such lesions had more consistent 5-HT expression.
  • [MeSH-major] Dog Diseases / metabolism. Mast-Cell Sarcoma / veterinary. Receptor, Serotonin, 5-HT1A / metabolism. Serotonin / metabolism. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Dogs. Fluorescent Antibody Technique, Direct / methods. Fluorescent Antibody Technique, Direct / veterinary. Immunoenzyme Techniques / methods. Immunoenzyme Techniques / veterinary. Mast Cells / metabolism. Neoplasm Staging / veterinary. Skin / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19446835.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 112692-38-3 / Receptor, Serotonin, 5-HT1A; 333DO1RDJY / Serotonin
  •  go-up   go-down






Advertisement